

Modular Program Report

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request cder_mpl1r_wp023_nsdp_v01

Request ID: cder_mpl1r_wp023_nsdp_v01

Query Tool: Cohort Identification and Descriptive Analysis Tool, version 2.2.0

Query Description: This report contains estimated numbers of idelalisib users and idelalisib users with concomitant use of several anti-cancer agents as well as cancer diagnoses around the time of idelalisib use.

Data Source: Data from July 23, 2014 to December 31, 2015 from 15 health plans contributing to the Sentinel Distributed Database (SDD) were included in this report. This request was distributed on May 19, 2016. See Appendix A for a list of the latest dates of available data for each Data Partner.

Study Design: This request was designed to determine concomitancy and indications for idelalisib use. It calculated the number of patients taking idelalisib and the number of patients taking idelalisib within the same time frame as 13 other specified agents. It also identified the cancer indication for each idelalisib episode, if the indication is present in the data. The number of qualifying patients with the exposure(s) of interest, number of eligible members, and member-days were calculated overall and were stratified by age group, sex, and year.

Exposure of Interest: The exposures of interest were idelalisib and concomitant use of idelalisib with each of the following 13 anti-tumor agents: bendamustine, bortezomib, chlorambucil, cyclophosphamide, doxorubicin, ibritumomab, ibrutinib, lenalidomide, obinutuzumab, ofatumumab, prednisone, rituximab, and vincristine. In order to be considered concomitant use, a patient must have used the second drug within 7 days prior to the start of the idelalisib exposure episode through 30 days following the end of the idelalisib exposure episode. Exposures were defined by National Drug Codes (NDCs) and Healthcare Common Procedure Coding System (HCPCS) codes. Please refer to Appendix B for generic and brand names and Appendix C for specific HCPCS codes used to define exposures.

Cohort Eligibility Criteria: Those included in the cohort were required to be enrolled in plans with both drug and medical coverage. No specific continuous enrollment time was required prior to the exposure of interest. Gaps in coverage of up to 45 days were allowed. The following age groups were included in the cohort: 18-44, 45-54, 55-64, and 65+ years.

Exposure Episodes: Exposure episode lengths were defined using outpatient pharmacy dispensing days supplied to create a sequence of continuous exposure. Exposure episodes were considered continuous if gaps in days supply were less than 30 days. All qualifying incident exposure episodes that occurred between July 23, 2014 and December 31, 2015 were examined.

Sensitivity Analyses: A sensitivity analysis was conducted to examine patients with three specific indications, in addition to patients with any indication. Specific indication groups include:

- 1) Chronic lymphocytic leukemia (CLL)
- 2) B-cell follicular non-Hodgkin lymphoma (FL)
- 3) Small lymphocytic lymphoma (SLL)

Individuals were required to have the indication of interest in the one year (365 days) prior or three months (90 days) following the idelalisib dispensing of interest. Indications were defined by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Please refer to Appendix D for specific codes used to define each indication.

Limitations: Algorithms to define exposures and indications are imperfect and, therefore, may be misclassified.

Please see Appendix E for the specifications of parameters to be used in the analyses for this request.

Notes: Please contact the Sentinel Operations Center Query Fulfillment Team (qt@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

Table of Contents

<u>Glossary</u>	List of Terms Found in this Report and their Definitions
<u>Table 1</u>	Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use and Indication
<u>Table 2</u>	Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Age Group
<u>Table 3</u>	Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex
<u>Table 4</u>	Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Year
<u>Appendix A</u>	Available Data in the Sentinel Distributed Database (SDD) as of May 19, 2016
<u>Appendix B</u>	Generic and Brand Drug Names used to Define Exposures in this Request
<u>Appendix C</u>	Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Exposures in this Request
<u>Appendix D</u>	International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Indications in this Request
<u>Appendix E</u>	Specifications for Request ID CDER_MPL1R_WP017_NS DP_V01
<u>Appendix F</u>	Count of Users, Episodes, Dispensings, Total Days Supplied, Years at risk, Eligible Members, Member-Years, Episodes with Events, and Number of Events by Scenario, Age Group, Sex, and Year

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Tool*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the "RxAmt" value in the Sentinel Common Data Model (SCDM).

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). Along with the Principal Diagnosis Indicator, forms the Care Setting/PDX parameter.

Cohort Definition (drug/exposure)- indicates how the cohort will be defined: (1) 01: Cohort includes only the first valid incident treatment episode during the query period; (2) 02: Cohort includes all valid incident treatment episodes during the query period; (3) 03: Cohort includes all valid incident treatment episodes during the query period until an event occurs.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the MP algorithm: (0) 0: Counts all occurrences of an HOI during an exposure episode; (1) 1: de-duplicates occurrences of the same HOI code and code type on the same day; (2) 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode.

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Lookback Period (pre-existing condition) - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the CareSetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Treatment Episode Truncation Indicator - indicates whether observation of the incident query code during follow-up requires truncation of valid treatment episodes. A value of Y indicates that the treatment episodes should be truncated at the first occurrence of an incident query code. A value of N indicates that the treatment episodes should not be truncated at the occurrence of the incident query code.

Users - number of members with exposure during the query period. Member must have no evidence of exposure(s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.

Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

**incident treatment episodes must be incident to both the exposure and the event

Table 1: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use and Indication

	Users	Dispensings	Days Supplied	Amount Supplied	Eligible Members with Indication	Member-Years	Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Any idelalisib use										
<i>Any Indication</i>	219	781	21,274	42,354	45,938,002	34,458,133.1	0.00	97.14	3.57	27.24
<i>Chronic lymphocytic leukemia (CLL)</i>	105	405	10,931	21,890	37,389	29,277.0	2.81	104.10	3.86	26.99
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	82	278	7,757	15,332	22,182	15,238.4	3.70	94.60	3.39	27.90
<i>Small lymphocytic lymphoma (SLL)</i>	171	575	15,782	31,342	86,698	60,976.1	1.97	92.29	3.36	27.45
	Users	Episodes	Percent of Total Idelalisib Users							
Idelalisib and Bendamustine										
<i>Any Indication</i>	9	9	4.11%							
<i>Chronic lymphocytic leukemia (CLL)</i>	1	1	0.95%							
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	3	3	3.66%							
<i>Small lymphocytic lymphoma (SLL)</i>	7	7	4.09%							
Idelalisib and Bortezomib										
<i>Any Indication</i>	2	2	0.91%							
<i>Chronic lymphocytic leukemia (CLL)</i>	0	0	0.00%							
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	0	0	0.00%							
<i>Small lymphocytic lymphoma (SLL)</i>	0	0	0.00%							
Idelalisib and Chlorambucil										
<i>Any Indication</i>	5	5	2.28%							
<i>Chronic lymphocytic leukemia (CLL)</i>	5	5	4.76%							
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	0	0	0.00%							
<i>Small lymphocytic lymphoma (SLL)</i>	3	3	1.75%							
Idelalisib and Cyclophosphamide										
<i>Any Indication</i>	2	2	0.91%							
<i>Chronic lymphocytic leukemia (CLL)</i>	0	0	0.00%							
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	1	1	1.22%							
<i>Small lymphocytic lymphoma (SLL)</i>	2	2	1.17%							
Idelalisib and Doxorubicin										
<i>Any Indication</i>	1	1	0.46%							
<i>Chronic lymphocytic leukemia (CLL)</i>	0	0	0.00%							
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	0	0	0.00%							
<i>Small lymphocytic lymphoma (SLL)</i>	0	0	0.00%							

Table 1: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use and Indication

Idelalisib and Ibrutinib			
<i>Any Indication</i>	0	0	0.00%
<i>Chronic lymphocytic leukemia (CLL)</i>	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>	0	0	0.00%
Idelalisib and Lenalidomide			
<i>Any Indication</i>	21	21	9.59%
<i>Chronic lymphocytic leukemia (CLL)</i>	15	15	14.29%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	2	2	2.44%
<i>Small lymphocytic lymphoma (SLL)</i>	15	15	8.77%
Idelalisib and Obinutuzumab			
<i>Any Indication</i>	4	4	1.83%
<i>Chronic lymphocytic leukemia (CLL)</i>	3	3	2.86%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	1	1	1.22%
<i>Small lymphocytic lymphoma (SLL)</i>	3	3	1.75%
Idelalisib and Ofatumumab			
<i>Any Indication</i>	2	2	0.91%
<i>Chronic lymphocytic leukemia (CLL)</i>	2	2	1.90%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>	0	0	0.00%
Idelalisib and Prednisone			
<i>Any Indication</i>	46	47	21.00%
<i>Chronic lymphocytic leukemia (CLL)</i>	29	29	27.62%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	13	13	15.85%
<i>Small lymphocytic lymphoma (SLL)</i>	34	35	19.88%

Table 1: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use and Indication

Idelalisib and Rituximab			
<i>Any Indication</i>	81	85	36.99%
<i>Chronic lymphocytic leukemia (CLL)</i>	51	55	48.57%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	24	24	29.27%
<i>Small lymphocytic lymphoma (SLL)</i>	60	62	35.09%
Idelalisib and Vincristine			
<i>Any Indication</i>	1	1	0.46%
<i>Chronic lymphocytic leukemia (CLL)</i>	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>	1	1	0.58%

Table 2: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Age Group

*A user may have multiple indications which may result in double counting

	Users	Dispensings	Days Supplied	Amount Supplied	Eligible Members with Indication	Member-Years	Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Any idelalisib use										
Any Indication										
18-44 Years	9	24	673	1,316	23,614,134	16,258,012.1	0.00	74.78	2.67	28.04
45-54 Years	26	93	2,528	5,026	9,304,524	6,575,969.8	0.00	97.23	3.58	27.18
55-64 Years	67	223	5,965	11,864	8,219,330	5,975,767.6	0.01	89.03	3.33	26.75
65+ Years	119	441	12,108	24,148	6,592,965	5,648,383.5	0.02	101.75	3.71	27.46
Chronic lymphocytic leukemia (CLL)										
18-44 Years	2	10	279	558	1,028	594.0	1.95	139.50	5.00	27.90
45-54 Years	5	10	282	564	3,173	2,063.2	1.58	56.40	2.00	28.20
55-64 Years	38	127	3,416	6,832	9,262	6,462.2	4.10	89.89	3.34	26.90
65+ Years	62	258	6,954	13,936	25,103	20,157.5	2.47	112.16	4.16	26.95
B-cell follicular non-Hodgkin lymphoma (FL)										
18-44 Years	5	9	244	488	2,015	1,195.7	2.48	48.80	1.80	27.11
45-54 Years	15	59	1,615	3,200	3,545	2,217.5	4.23	107.67	3.93	27.37
55-64 Years	18	74	1,944	3,832	6,511	4,249.9	2.76	108.00	4.11	26.27
65+ Years	44	136	3,954	7,812	10,917	7,575.3	4.03	89.86	3.09	29.07
Small lymphocytic lymphoma (SLL)										
18-44 Years	7	13	364	698	11,206	6,918.1	0.62	52.00	1.86	28.00
45-54 Years	25	90	2,452	4,874	12,933	8,140.3	1.93	98.08	3.60	27.24
55-64 Years	48	165	4,515	8,964	22,742	14,936.2	2.11	94.06	3.44	27.36
65+ Years	92	307	8,451	16,806	42,871	30,981.4	2.15	91.86	3.34	27.53

	Users	Episodes	Percent of Total Idelalisib Users
Idelalisib and Bendamustine			
Any Indication			
18-44 Years	1	1	11.11%
45-54 Years	0	0	0.00%
55-64 Years	4	4	5.97%
65+ Years	4	4	3.36%
Chronic lymphocytic leukemia (CLL)			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	1	1	2.63%
65+ Years	0	0	0.00%
B-cell follicular non-Hodgkin lymphoma (FL)			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	1	1	5.56%
65+ Years	2	2	4.55%
Small lymphocytic lymphoma (SLL)			
18-44 Years	1	1	14.29%
45-54 Years	0	0	0.00%
55-64 Years	2	2	4.17%
65+ Years	4	4	4.35%

Table 2: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Age Group

Idelalisib and Bortezomib			
<i>Any Indication</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	2	2	2.99%
65+ Years	0	0	0.00%
<i>Chronic lymphocytic leukemia (CLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
Idelalisib and Chlorambucil			
<i>Any Indication</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	4	4	5.97%
65+ Years	1	1	0.84%
<i>Chronic lymphocytic leukemia (CLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	4	4	10.53%
65+ Years	1	1	1.61%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	3	3	6.25%
65+ Years	0	0	0.00%

Table 2: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Age Group

Idelalisib and Cyclophosphamide			
<i>Any Indication</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	2	2	1.68%
Chronic lymphocytic leukemia (CLL)			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
B-cell follicular non-Hodgkin lymphoma (FL)			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	1	1	2.27%
Small lymphocytic lymphoma (SLL)			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	2	2	2.17%
Idelalisib and Doxorubicin			
<i>Any Indication</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	1	1	1.49%
65+ Years	0	0	0.00%
Chronic lymphocytic leukemia (CLL)			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
B-cell follicular non-Hodgkin lymphoma (FL)			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
Small lymphocytic lymphoma (SLL)			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%

Table 2: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Age Group

Idelalisib and Ibritumomab			
<i>Any Indication</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
<i>Chronic lymphocytic leukemia (CLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
Idelalisib and Ibrutinib			
<i>Any Indication</i>			
18-44 Years	2	2	22.22%
45-54 Years	2	2	7.69%
55-64 Years	8	8	11.94%
65+ Years	9	9	7.56%
<i>Chronic lymphocytic leukemia (CLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	2	2	40.00%
55-64 Years	6	6	15.79%
65+ Years	7	7	11.29%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
18-44 Years	1	1	20.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	1	1	2.27%
<i>Small lymphocytic lymphoma (SLL)</i>			
18-44 Years	2	2	28.57%
45-54 Years	2	2	8.00%
55-64 Years	5	5	10.42%
65+ Years	6	6	6.52%

Table 2: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Age Group

Idelalisib and Lenalidomide			
<i>Any Indication</i>			
18-44 Years	1	1	11.11%
45-54 Years	0	0	0.00%
55-64 Years	1	1	1.49%
65+ Years	3	3	2.52%
<i>Chronic lymphocytic leukemia (CLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
18-44 Years	1	1	20.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	1	1	2.27%
<i>Small lymphocytic lymphoma (SLL)</i>			
18-44 Years	1	1	14.29%
45-54 Years	0	0	0.00%
55-64 Years	1	1	2.08%
65+ Years	3	3	3.26%
Idelalisib and Obinutuzumab			
<i>Any Indication</i>			
18-44 Years	1	1	11.11%
45-54 Years	0	0	0.00%
55-64 Years	1	1	1.49%
65+ Years	2	2	1.68%
<i>Chronic lymphocytic leukemia (CLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	1	1	2.63%
65+ Years	2	2	3.23%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	1	1	2.27%
<i>Small lymphocytic lymphoma (SLL)</i>			
18-44 Years	1	1	14.29%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	2	2	2.17%

Table 2: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Age Group

Idelalisib and Ofatumumab			
<i>Any Indication</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	2	2	1.68%
<i>Chronic lymphocytic leukemia (CLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	2	2	3.23%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
Idelalisib and Prednisone			
<i>Any Indication</i>			
18-44 Years	2	2	22.22%
45-54 Years	3	3	11.54%
55-64 Years	17	17	25.37%
65+ Years	24	25	20.17%
<i>Chronic lymphocytic leukemia (CLL)</i>			
18-44 Years	1	1	50.00%
45-54 Years	1	1	20.00%
55-64 Years	12	12	31.58%
65+ Years	15	15	24.19%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	2	2	13.33%
55-64 Years	4	4	22.22%
65+ Years	7	7	15.91%
<i>Small lymphocytic lymphoma (SLL)</i>			
18-44 Years	1	1	14.29%
45-54 Years	3	3	12.00%
55-64 Years	14	14	29.17%
65+ Years	16	17	17.39%

Table 2: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Age Group

Idelalisib and Rituximab			
<i>Any Indication</i>			
18-44 Years	2	2	22.22%
45-54 Years	8	8	30.77%
55-64 Years	24	25	35.82%
65+ Years	47	50	39.50%
<i>Chronic lymphocytic leukemia (CLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	2	2	40.00%
55-64 Years	18	19	47.37%
65+ Years	31	34	50.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
18-44 Years	1	1	20.00%
45-54 Years	5	5	33.33%
55-64 Years	3	3	16.67%
65+ Years	15	15	34.09%
<i>Small lymphocytic lymphoma (SLL)</i>			
18-44 Years	2	2	28.57%
45-54 Years	8	8	32.00%
55-64 Years	16	16	33.33%
65+ Years	34	36	36.96%
Idelalisib and Vincristine			
<i>Any Indication</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	1	1	0.84%
<i>Chronic lymphocytic leukemia (CLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	0	0	0.00%
65+ Years	1	1	1.09%

Table 3: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex

	Users	Dispensings	Days Supplied	Amount Supplied	Eligible Members with Indication	Member-Years	Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Any idelalisib use										
Any Indication										
Female	96	336	9,272	18,502	23,519,031	17,719,236.5	0.00	96.58	3.50	27.60
Male	123	445	12,002	23,852	22,416,713	16,737,341.4	0.01	97.58	3.62	26.97
Unknown	0	0	0	0	2,258	1,555.1	0.00	---	---	---
Chronic lymphocytic leukemia (CLL)										
Female	40	164	4,529	9,086	15,900	12,461.7	2.52	113.23	4.10	27.62
Male	65	241	6,402	12,804	21,487	16,814.0	3.03	98.49	3.71	26.56
Unknown	0	0	0	0	2	1.3	0.00	---	---	---
B-cell follicular non-Hodgkin lymphoma (FL)										
Female	38	121	3,380	6,730	11,031	7,610.8	3.44	88.95	3.18	27.93
Male	44	157	4,377	8,602	11,151	7,627.6	3.95	99.48	3.57	27.88
Unknown	0	0	0	0	0	0.0	---	---	---	---
Small lymphocytic lymphoma (SLL)										
Female	74	235	6,502	12,934	41,121	29,089.2	1.80	87.86	3.18	27.67
Male	97	340	9,280	18,408	45,573	31,884.3	2.13	95.67	3.51	27.29
Unknown	0	0	0	0	4	2.6	0.00	---	---	---

	Users	Episodes	Percent of Total Idelalisib Users
Idelalisib and Bendamustine			
Any Indication			
Female	4	4	4.17%
Male	5	5	4.07%
Unknown	0	0	---
Chronic lymphocytic leukemia (CLL)			
Female	0	0	0.00%
Male	1	1	1.54%
Unknown	0	0	---
B-cell follicular non-Hodgkin lymphoma (FL)			
Female	1	1	2.63%
Male	2	2	4.55%
Unknown	0	0	---
Small lymphocytic lymphoma (SLL)			
Female	3	3	4.05%
Male	4	4	4.12%
Unknown	0	0	---

Table 3: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex

Idelalisib and Bortezomib			
<i>Any Indication</i>			
Female	0	0	0.00%
Male	2	2	1.63%
Unknown	0	0	---
<i>Chronic lymphocytic leukemia (CLL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>Small lymphocytic lymphoma (SLL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
Idelalisib and Chlorambucil			
<i>Any Indication</i>			
Female	2	2	2.08%
Male	3	3	2.44%
Unknown	0	0	---
<i>Chronic lymphocytic leukemia (CLL)</i>			
Female	2	2	5.00%
Male	3	3	4.62%
Unknown	0	0	---
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>Small lymphocytic lymphoma (SLL)</i>			
Female	2	2	2.70%
Male	1	1	1.03%
Unknown	0	0	---

Table 3: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex

Idelalisib and Cyclophosphamide			
<i>Any Indication</i>			
Female	1	1	1.04%
Male	1	1	0.81%
Unknown	0	0	---
<i>Chronic lymphocytic leukemia (CLL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
Female	0	0	0.00%
Male	1	1	2.27%
Unknown	0	0	---
<i>Small lymphocytic lymphoma (SLL)</i>			
Female	1	1	1.35%
Male	1	1	1.03%
Unknown	0	0	---
Idelalisib and Doxorubicin			
<i>Any Indication</i>			
Female	0	0	0.00%
Male	1	1	0.81%
Unknown	0	0	---
<i>Chronic lymphocytic leukemia (CLL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>Small lymphocytic lymphoma (SLL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
Idelalisib and Ibritumomab			
<i>Any Indication</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>Chronic lymphocytic leukemia (CLL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>Small lymphocytic lymphoma (SLL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---

Table 3: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex

Idelalisib and Ibrutinib			
<i>Any Indication</i>			
Female	7	7	7.29%
Male	14	14	11.38%
Unknown	0	0	---
<i>Chronic lymphocytic leukemia (CLL)</i>			
Female	4	4	10.00%
Male	11	11	16.92%
Unknown	0	0	---
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
Female	1	1	2.63%
Male	1	1	2.27%
Unknown	0	0	---
<i>Small lymphocytic lymphoma (SLL)</i>			
Female	6	6	8.11%
Male	9	9	9.28%
Unknown	0	0	---
Idelalisib and Lenalidomide			
<i>Any Indication</i>			
Female	3	3	3.13%
Male	2	2	1.63%
Unknown	0	0	---
<i>Chronic lymphocytic leukemia (CLL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
Female	1	1	2.63%
Male	1	1	2.27%
Unknown	0	0	---
<i>Small lymphocytic lymphoma (SLL)</i>			
Female	3	3	4.05%
Male	2	2	2.06%
Unknown	0	0	---
Idelalisib and Obinutuzumab			
<i>Any Indication</i>			
Female	2	2	2.08%
Male	2	2	1.63%
Unknown	0	0	---
<i>Chronic lymphocytic leukemia (CLL)</i>			
Female	1	1	2.50%
Male	2	2	3.08%
Unknown	0	0	---
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
Female	1	1	2.63%
Male	0	0	0.00%
Unknown	0	0	---
<i>Small lymphocytic lymphoma (SLL)</i>			
Female	2	2	2.70%
Male	1	1	1.03%
Unknown	0	0	---

Table 3: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex

Idelalisib and Ofatumumab			
Any Indication			
Female	1	1	1.04%
Male	1	1	0.81%
Unknown	0	0	---
Chronic lymphocytic leukemia (CLL)			
Female	1	1	2.50%
Male	1	1	1.54%
Unknown	0	0	---
B-cell follicular non-Hodgkin lymphoma (FL)			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
Small lymphocytic lymphoma (SLL)			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
Idelalisib and Prednisone			
Any Indication			
Female	17	18	17.71%
Male	29	29	23.58%
Unknown	0	0	---
Chronic lymphocytic leukemia (CLL)			
Female	8	8	20.00%
Male	21	21	32.31%
Unknown	0	0	---
B-cell follicular non-Hodgkin lymphoma (FL)			
Female	6	6	15.79%
Male	7	7	15.91%
Unknown	0	0	---
Small lymphocytic lymphoma (SLL)			
Female	14	15	18.92%
Male	20	20	20.62%
Unknown	0	0	---
Idelalisib and Rituximab			
Any Indication			
Female	29	29	30.21%
Male	52	56	42.28%
Unknown	0	0	---
Chronic lymphocytic leukemia (CLL)			
Female	19	19	47.50%
Male	32	36	49.23%
Unknown	0	0	---
B-cell follicular non-Hodgkin lymphoma (FL)			
Female	9	9	23.68%
Male	15	15	34.09%
Unknown	0	0	---
Small lymphocytic lymphoma (SLL)			
Female	17	17	22.97%
Male	43	45	44.33%
Unknown	0	0	---

Table 3: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex

Idelalisib and Vincristine			
<i>Any Indication</i>			
Female	1	1	1.04%
Male	0	0	0.00%
Unknown	0	0	---
<i>Chronic lymphocytic leukemia (CLL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
Female	0	0	0.00%
Male	0	0	0.00%
Unknown	0	0	---
<i>Small lymphocytic lymphoma (SLL)</i>			
Female	1	1	1.35%
Male	0	0	0.00%
Unknown	0	0	---

Table 4: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Year

	Users	Dispensings	Days Supplied	Amount Supplied	Eligible Members with Indication	Member-Years	Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Any idelalisib use										
<i>Any Indication</i>										
2014	99	212	6,064	12,068	37,580,728	14,924,033.6	0.00	61.25	2.14	28.60
2015	169	569	15,210	30,286	38,386,167	19,534,099.5	0.00	90.00	3.37	26.73
<i>Chronic lymphocytic leukemia (CLL)</i>										
2014	47	106	3,061	6,122	32,634	12,875.6	1.44	65.13	2.26	28.88
2015	84	299	7,870	15,768	31,284	16,401.4	2.69	93.69	3.56	26.32
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>										
2014	43	91	2,614	5,198	19,019	7,024.3	2.26	60.79	2.12	28.73
2015	58	187	5,143	10,134	17,326	8,214.2	3.35	88.67	3.22	27.50
<i>Small lymphocytic lymphoma (SLL)</i>										
2014	83	172	4,940	9,820	74,416	27,766.1	1.12	59.52	2.07	28.72
2015	126	403	10,842	21,522	68,805	33,210.0	1.83	86.05	3.20	26.90

	Users	Episodes	Percent of Total Idelalisib Users
Idelalisib and Bendamustine			
<i>Any Indication</i>			
2014	5	5	5.05%
2015	4	4	2.37%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	1	1	2.13%
2015	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	2	2	4.65%
2015	1	1	1.72%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	4	4	4.82%
2015	3	3	2.38%
Idelalisib and Bortezomib			
<i>Any Indication</i>			
2014	2	2	2.02%
2015	0	0	0.00%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%

Table 4: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Year

Idelalisib and Chlorambucil			
<i>Any Indication</i>			
2014	3	3	3.03%
2015	2	2	1.18%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	3	3	6.38%
2015	2	2	2.38%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	2	2	2.41%
2015	1	1	0.79%
Idelalisib and Cyclophosphamide			
<i>Any Indication</i>			
2014	2	2	2.02%
2015	0	0	0.00%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	1	1	2.33%
2015	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	2	2	2.41%
2015	0	0	0.00%
Idelalisib and Doxorubicin			
<i>Any Indication</i>			
2014	1	1	1.01%
2015	0	0	0.00%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
Idelalisib and Ibritumomab			
<i>Any Indication</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%

Table 4: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Year

Idelalisib and Ibrutinib			
<i>Any Indication</i>			
2014	15	15	15.15%
2015	6	6	3.55%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	9	9	19.15%
2015	6	6	7.14%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	2	2	4.65%
2015	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	12	12	14.46%
2015	3	3	2.38%
Idelalisib and Lenalidomide			
<i>Any Indication</i>			
2014	4	4	4.04%
2015	1	1	0.59%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	2	2	4.65%
2015	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	4	4	4.82%
2015	1	1	0.79%
Idelalisib and Obinutuzumab			
<i>Any Indication</i>			
2014	3	3	3.03%
2015	1	1	0.59%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	2	2	4.26%
2015	1	1	1.19%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	1	1	2.33%
2015	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	3	3	3.61%
2015	0	0	0.00%
Idelalisib and Ofatumumab			
<i>Any Indication</i>			
2014	2	2	2.02%
2015	0	0	0.00%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	2	2	4.26%
2015	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%

Table 4: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Year

Idelalisib and Prednisone			
<i>Any Indication</i>			
2014	20	20	20.20%
2015	26	27	15.38%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	11	11	23.40%
2015	18	18	21.43%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	8	8	18.60%
2015	5	5	8.62%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	17	17	20.48%
2015	17	18	13.49%
Idelalisib and Rituximab			
<i>Any Indication</i>			
2014	42	42	42.42%
2015	41	43	24.26%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	25	25	53.19%
2015	28	30	33.33%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	15	15	34.88%
2015	9	9	15.52%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	32	32	38.55%
2015	29	30	23.02%
Idelalisib and Vincristine			
<i>Any Indication</i>			
2014	1	1	1.01%
2015	0	0	0.00%
<i>Chronic lymphocytic leukemia (CLL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>B-cell follicular non-Hodgkin lymphoma (FL)</i>			
2014	0	0	0.00%
2015	0	0	0.00%
<i>Small lymphocytic lymphoma (SLL)</i>			
2014	1	1	1.20%
2015	0	0	0.00%

Appendix A: Available Data in the Sentinel Distributed Database (SDD) as of May 19, 2016

DP ID	Start Date	End Date
DP0001	7/23/2014	9/30/2015
DP0002	7/23/2014	4/30/2015
DP0003	7/23/2014	10/31/2014
DP0004	7/23/2014	6/30/2015
DP0005	7/23/2014	2/28/2015
DP0006	7/23/2014	7/31/2014
DP0007	7/23/2014	6/30/2012
DP0008	7/23/2014	7/31/2015
DP0009	7/23/2014	10/31/2015
DP0010	7/23/2014	11/30/2015
DP0011	7/23/2014	9/30/2015
DP0012	7/23/2014	12/31/2015
DP0013	7/23/2014	11/30/2015
DP0014	7/23/2014	6/30/2015
DP0015	7/23/2014	12/31/2014

Appendix B: Generic and Brand Drug Names used to Define Exposures in this Request

Generic Name	Brand Name
DOXORUBICIN HCL	Adriamycin
DOXORUBICIN HCL	Adriamycin PFS
OFATUMUMAB	Arzerra
BENDAMUSTINE HCL	Bendeka
CHLORAMBUCIL	chlorambucil
CYCLOPHOSPHAMIDE	cyclophosphamide
CYCLOPHOSPHAMIDE	cyclophosphamide (bulk)
PREDNISONE	Deltasone
DOXORUBICIN HCL PEGYLATED LIPOSOMAL	Doxil
DOXORUBICIN HCL	doxorubicin
DOXORUBICIN HCL PEGYLATED LIPOSOMAL	doxorubicin, peg-liposomal
OBINUTUZUMAB	Gazyva
IBRUTINIB	Imbruvica
CHLORAMBUCIL	Leukeran
DOXORUBICIN HCL PEGYLATED LIPOSOMAL	Lipodox
DOXORUBICIN HCL PEGYLATED LIPOSOMAL	Lipodox 50
VINCRIStINE SULFATE LIPOSOMAL	Marqibo
PREDNISONE	prednisone
PREDNISONE	Prednisone Intensol
PREDNISONE MICRONIZED	prednisone micronized (bulk)
PREDNISONE	Rayos
LENALIDOMIDE	Revlimid
RITUXIMAB	Rituxan
BENDAMUSTINE HCL	Treanda
BORTEZOMIB	Velcade
VINCRIStINE SULFATE	Vincasar PFS
VINCRIStINE SULFATE	vincristine
KIT FOR PREP INDIUM-111/IBRITUMOMAB TIUXETAN/ALBUMIN HUMAN	Zevalin (In-111)
KIT FOR PREP YTTRIUM-90/IBRITUMOMAB TIUXETAN/ALBUMIN HUMAN	Zevalin (Y-90)
IDELALISIB	Zydelig

Appendix C: Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Exposures in this Request

Code	Code Type	Description
Bendamustine		
J9033	HCPCS	Injection, bendamustine HCl, 1 mg
Bortezomib		
J9041	HCPCS	Injection, bortezomib, 0.1 mg
Chlorambucil		
S0172	HCPCS	Chlorambucil, oral, 2 mg
Cyclophosphamide		
J8530	HCPCS	Cyclophosphamide, oral, 25 mg
J9070	HCPCS	Cyclophosphamide, 100 mg
Doxorubicin		
J9000	HCPCS	Injection, doxorubicin HCl, 10 mg
Q2049	HCPCS	Injection, doxorubicin hydrochloride, liposomal, imported Lipodox, 10 mg
Q2050	HCPCS	Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Ibritumomab		
A9542	HCPCS	Indium In-111 ibritumomab tiuxetan, diagnostic, per study dose, up to 5 millicuries
A9543	HCPCS	Yttrium Y-90 ibritumomab tiuxetan, therapeutic, per treatment dose, up to 40 millicuries
Obinutuzumab		
C9021	HCPCS	Injection, obinutuzumab, 10 mg
J9301	HCPCS	Injection, obinutuzumab, 10 mg
Ofatumumab		
J9302	HCPCS	Injection, ofatumumab, 10 mg
Prednisone		
J7506	HCPCS	Prednisone, oral, per 5 mg
Rituximab		
J9310	HCPCS	Injection, rituximab, 100 mg
Vincristine		
J9370	HCPCS	Vincristine sulfate, 1 mg
J9371	HCPCS	Injection, vincristine sulfate liposome, 1 mg

Appendix D: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Indications in this Request

Code	Code Type	Description
Chronic lymphocytic leukemia (CLL)		
204.1	ICD-9-CM	Chronic Lymphoid Leukemia, any
204.10	ICD-9-CM	Chronic Lymphoid Leukemia, no prior
204.11	ICD-9-CM	Chronic Lymphoid Leukemia, remission
204.12	ICD-9-CM	Chronic Lymphoid Leukemia, relapse
C91.1	ICD-10-CM	Chronic Lymphoid Leukemia, any
C91.10	ICD-10-CM	Chronic Lymphoid Leukemia, no prior
C91.11	ICD-10-CM	Chronic Lymphoid Leukemia, remission
C91.12	ICD-10-CM	Chronic Lymphoid Leukemia, relapse
Small lymphocytic lymphoma (SLL)		
202.8	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas)
202.80	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, unspecified extranodal solid organ)
202.81	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, head face neck)
202.82	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, intrathoracic)
202.83	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, intra-abdominal)
202.84	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, axilla upper limb)
202.85	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, inguinal lower limb)
202.86	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, intrapelvic)
202.87	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, spleen)
202.88	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, multiple)
83.0	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma)
83.00	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, unspecified)
83.01	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, head face neck)
83.02	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, intrathoracic)
83.03	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, intra-abdominal)
83.04	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, axilla upper limb)
83.04	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, inguinal lower limb)
83.06	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, intrapelvic)
83.07	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, spleen)
83.08	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, multiple)
83.09	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, extranodal solid organ)
B-cell follicular non-Hodgkin lymphoma (FL)		
202.0	ICD-9-CM	Follicular lymphoma (Nodular lymphoma)
202.00	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, unspecified extranodal solid organ)
202.01	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, head face neck)
202.02	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, intrathoracic)
202.03	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, intra-abdominal)
202.04	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, axilla upper limb)
202.05	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, inguinal lower limb)
202.06	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, intrapelvic)
202.07	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, spleen)
202.08	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, multiple)
C82	ICD-10-CM	Follicular lymphoma, any
C82.0	ICD-10-CM	Follicular lymphoma grade I,
C82.00	ICD-10-CM	Follicular lymphoma grade I, unspecified site
C82.01	ICD-10-CM	Follicular lymphoma grade I, lymph nodes of head, face, and neck
C82.02	ICD-10-CM	Follicular lymphoma grade I, intrathoracic lymph nodes
C82.03	ICD-10-CM	Follicular lymphoma grade I, intra-abdominal lymph nodes
C82.04	ICD-10-CM	Follicular lymphoma grade I, lymph nodes of axilla and upper limb
C82.05	ICD-10-CM	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb
C82.06	ICD-10-CM	Follicular lymphoma grade I, intrapelvic lymph nodes
C82.07	ICD-10-CM	Follicular lymphoma grade I, spleen
C82.08	ICD-10-CM	Follicular lymphoma grade I, lymph nodes of multiple sites
C82.09	ICD-10-CM	Follicular lymphoma grade I, extranodal and solid organ sites
C82.1	ICD-10-CM	Follicular lymphoma grade II,
C82.10	ICD-10-CM	Follicular lymphoma grade II, unspecified site
C82.11	ICD-10-CM	Follicular lymphoma grade II, lymph nodes of head, face, and neck
C82.12	ICD-10-CM	Follicular lymphoma grade II, intrathoracic lymph nodes

B-cell follicular non-Hodgkin lymphoma (FL)

C82.13	ICD-10-CM	Follicular lymphoma grade II, intra-abdominal lymph nodes
C82.14	ICD-10-CM	Follicular lymphoma grade II, lymph nodes of axilla and upper limb
C82.15	ICD-10-CM	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb
C82.16	ICD-10-CM	Follicular lymphoma grade II, intrapelvic lymph nodes
C82.17	ICD-10-CM	Follicular lymphoma grade II, spleen
C82.18	ICD-10-CM	Follicular lymphoma grade II, lymph nodes of multiple sites
C82.19	ICD-10-CM	Follicular lymphoma grade II, extranodal and solid organ sites
C82.2	ICD-10-CM	Follicular lymphoma grade III,
C82.20	ICD-10-CM	Follicular lymphoma grade III, unspecified site
C82.21	ICD-10-CM	Follicular lymphoma grade III, lymph nodes of head, face, and neck
C82.22	ICD-10-CM	Follicular lymphoma grade III, intrathoracic lymph nodes
C82.23	ICD-10-CM	Follicular lymphoma grade III, intra-abdominal lymph nodes
C82.24	ICD-10-CM	Follicular lymphoma grade III, lymph nodes of axilla and upper limb
C82.25	ICD-10-CM	Follicular lymphoma grade III, lymph nodes of inguinal region and lower limb
C82.26	ICD-10-CM	Follicular lymphoma grade III, intrapelvic lymph nodes
C82.27	ICD-10-CM	Follicular lymphoma grade III, spleen
C82.28	ICD-10-CM	Follicular lymphoma grade III, lymph nodes of multiple sites
C82.29	ICD-10-CM	Follicular lymphoma grade III, extranodal and solid organ sites
C82.3	ICD-10-CM	Follicular lymphoma grade IIIa,
C82.30	ICD-10-CM	Follicular lymphoma grade IIIa, unspecified site
C82.31	ICD-10-CM	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck
C82.32	ICD-10-CM	Follicular lymphoma grade IIIa, intrathoracic lymph nodes
C82.33	ICD-10-CM	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
C82.34	ICD-10-CM	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb
C82.35	ICD-10-CM	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb
C82.36	ICD-10-CM	Follicular lymphoma grade IIIa, intrapelvic lymph nodes
C82.37	ICD-10-CM	Follicular lymphoma grade IIIa, spleen
C82.38	ICD-10-CM	Follicular lymphoma grade IIIa, lymph nodes of multiple sites
C82.39	ICD-10-CM	Follicular lymphoma grade IIIa, extranodal and solid organ sites
C82.4	ICD-10-CM	Follicular lymphoma grade IIIb,
C82.40	ICD-10-CM	Follicular lymphoma grade IIIb, unspecified site
C82.41	ICD-10-CM	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck
C82.42	ICD-10-CM	Follicular lymphoma grade IIIb, intrathoracic lymph nodes
C82.43	ICD-10-CM	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes
C82.44	ICD-10-CM	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb
C82.45	ICD-10-CM	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb
C82.46	ICD-10-CM	Follicular lymphoma grade IIIb, intrapelvic lymph nodes
C82.47	ICD-10-CM	Follicular lymphoma grade IIIb, spleen
C82.48	ICD-10-CM	Follicular lymphoma grade IIIb, lymph nodes of multiple sites
C82.49	ICD-10-CM	Follicular lymphoma grade IIIb, extranodal and solid organ sites
C82.5	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma,)
C82.50	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, unspecified site)
C82.51	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, lymph nodes of head, face, and neck)
C82.52	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, intrathoracic lymph nodes)
C82.53	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, intra-abdominal lymph nodes)
C82.54	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb)
C82.55	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb)
C82.56	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, intrapelvic lymph nodes)
C82.57	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, spleen)
C82.58	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, lymph nodes of multiple sites)
C82.59	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, extranodal and solid organ sites)
C82.6	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma,)
C82.60	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, unspecified site)
C82.61	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck)
C82.62	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, intrathoracic lymph nodes)
C82.63	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, intra-abdominal lymph nodes)
C82.64	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb)
C82.65	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb)
C82.66	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, intrapelvic lymph nodes)
C82.67	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, spleen)

B-cell follicular non-Hodgkin lymphoma (FL)

C82.68	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, lymph nodes of multiple sites)
C82.69	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, extranodal and solid organ sites)
C82.8	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma,)
C82.80	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, unspecified site)
C82.81	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, lymph nodes of head, face, and neck)
C82.82	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, intrathoracic lymph nodes)
C82.83	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, intra-abdominal lymph nodes)
C82.84	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, lymph nodes of axilla and upper limb)
C82.85	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb)
C82.86	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, intrapelvic lymph nodes)
C82.87	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, spleen)
C82.88	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, lymph nodes of multiple sites)
C82.89	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, extranodal and solid organ sites)
C82.9	ICD-10-CM	Follicular lymphoma, unspecified,
C82.90	ICD-10-CM	Follicular lymphoma, unspecified, unspecified site
C82.91	ICD-10-CM	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck
C82.92	ICD-10-CM	Follicular lymphoma, unspecified, intrathoracic lymph nodes
C82.93	ICD-10-CM	Follicular lymphoma, unspecified, intra-abdominal lymph nodes
C82.94	ICD-10-CM	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb
C82.95	ICD-10-CM	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C82.96	ICD-10-CM	Follicular lymphoma, unspecified, intrapelvic lymph nodes
C82.97	ICD-10-CM	Follicular lymphoma, unspecified, spleen
C82.98	ICD-10-CM	Follicular lymphoma, unspecified, lymph nodes of multiple sites
C82.99	ICD-10-CM	Follicular lymphoma, unspecified, extranodal and solid organ sites

Appendix E: Specifications for Request ID CDER_MPL1R_WP017_NSDP_V01

The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, v 2.2.0, to investigate idelalisib (Zydelig®) use and concomitant use of idelalisib with several anti-cancer agents among patients with various indications in the Sentinel Distributed Database (SDD).

Enrollment Gap: 45 days
Age Groups: 18-44, 45-54, 55-64, 65+
Query Period: July 23, 2014 - All available data
Pre-Exposure Enrollment Requirement: 0 days
Coverage Requirement: Drug and Medical

Scenario	Drug/Exposure					Concomitant Use Criteria						Inclusion Criteria			
	Incident Exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Min Days Supplied	Min Episode Duration	Concomitant Exposure	Lookback Start	Lookback End	Inclusion Condition	Care Setting	Lookback Start	Lookback End
1	Idelalisib	N/A	0	Include all valid incident index dates during the query period	N/A	0	0	0	None	N/A	N/A	CLL	Any	-365	90
2	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bendamustine	-7	30 days following end of treatment	CLL	Any	-365	90
3	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bortezomib	-7	30 days following end of treatment	CLL	Any	-365	90
4	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Chlorambucil	-7	30 days following end of treatment	CLL	Any	-365	90
5	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Cyclophosphamide	-7	30 days following end of treatment	CLL	Any	-365	90
6	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Doxorubicin	-7	30 days following end of treatment	CLL	Any	-365	90
7	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibrutinomab	-7	30 days following end of treatment	CLL	Any	-365	90
8	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibrutinib	-7	30 days following end of treatment	CLL	Any	-365	90
9	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Lenalidomide	-7	30 days following end of treatment	CLL	Any	-365	90
10	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Obinutuzumab	-7	30 days following end of treatment	CLL	Any	-365	90
11	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ofatumumab	-7	30 days following end of treatment	CLL	Any	-365	90
12	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Prednisone	-7	30 days following end of treatment	CLL	Any	-365	90

Scenario	Drug/Exposure				Concomitant Use Criteria							Inclusion Criteria			
	Incident Exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Min Days Supplied	Min Episode Duration	Concomitant Exposure	Lookback Start	Lookback End	Inclusion Condition	Care Setting	Lookback Start	Lookback End
13	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Rituximab	-7	30 days following end of treatment	CLL	Any	-365	90
14	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Vincristine	-7	30 days following end of treatment	CLL	Any	-365	90
15	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	None	N/A	N/A	FL	Any	-365	90
16	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bendamustine	-7	30 days following end of treatment	FL	Any	-365	90
17	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bortezomib	-7	30 days following end of treatment	FL	Any	-365	90
18	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Chlorambucil	-7	30 days following end of treatment	FL	Any	-365	90
19	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Cyclophosphamide	-7	30 days following end of treatment	FL	Any	-365	90
20	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Doxorubicin	-7	30 days following end of treatment	FL	Any	-365	90
21	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibrutinib	-7	30 days following end of treatment	FL	Any	-365	90
22	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibrutinib	-7	30 days following end of treatment	FL	Any	-365	90
23	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Lenalidomide	-7	30 days following end of treatment	FL	Any	-365	90
24	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Obinutuzumab	-7	30 days following end of treatment	FL	Any	-365	90
25	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ofatumumab	-7	30 days following end of treatment	FL	Any	-365	90
26	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Prednisone	-7	30 days following end of treatment	FL	Any	-365	90
27	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Rituximab	-7	30 days following end of treatment	FL	Any	-365	90
28	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Vincristine	-7	30 days following end of treatment	FL	Any	-365	90

Scenario	Drug/Exposure				Concomitant Use Criteria							Inclusion Criteria			
	Incident Exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Min Days Supplied	Min Episode Duration	Concomitant Exposure	Lookback Start	Lookback End	Inclusion Condition	Care Setting	Lookback Start	Lookback End
29	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	None	N/A	N/A	SLL	Any	-365	90
30	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bendamustine	-7	30 days following end of treatment	SLL	Any	-365	90
31	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bortezomib	-7	30 days following end of treatment	SLL	Any	-365	90
32	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Chlorambucil	-7	30 days following end of treatment	SLL	Any	-365	90
33	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Cyclophosphamide	-7	30 days following end of treatment	SLL	Any	-365	90
34	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Doxorubicin	-7	30 days following end of treatment	SLL	Any	-365	90
35	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibritumomab	-7	30 days following end of treatment	SLL	Any	-365	90
36	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibrutinib	-7	30 days following end of treatment	SLL	Any	-365	90
37	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Lenalidomide	-7	30 days following end of treatment	SLL	Any	-365	90
38	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Obinutuzumab	-7	30 days following end of treatment	SLL	Any	-365	90
39	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ofatumumab	-7	30 days following end of treatment	SLL	Any	-365	90
40	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Prednisone	-7	30 days following end of treatment	SLL	Any	-365	90
41	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Rituximab	-7	30 days following end of treatment	SLL	Any	-365	90
42	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Vincristine	-7	30 days following end of treatment	SLL	Any	-365	90
43	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	None	N/A	N/A	None	N/A	N/A	N/A
44	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bendamustine	-7	30 days following end of treatment	None	N/A	N/A	N/A

Scenario	Drug/Exposure				Concomitant Use Criteria							Inclusion Criteria			
	Incident Exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Min Days Supplied	Min Episode Duration	Concomitant Exposure	Lookback Start	Lookback End	Inclusion Condition	Care Setting	Lookback Start	Lookback End
45	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bortezomib	-7	30 days following end of treatment	None	N/A	N/A	N/A
46	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Chlorambucil	-7	30 days following end of treatment	None	N/A	N/A	N/A
47	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Cyclophosphamide	-7	30 days following end of treatment	None	N/A	N/A	N/A
48	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Doxorubicin	-7	30 days following end of treatment	None	N/A	N/A	N/A
49	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibrutinomab	-7	30 days following end of treatment	None	N/A	N/A	N/A
50	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibrutinib	-7	30 days following end of treatment	None	N/A	N/A	N/A
51	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Lenalidomide	-7	30 days following end of treatment	None	N/A	N/A	N/A
52	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Obinutuzumab	-7	30 days following end of treatment	None	N/A	N/A	N/A
53	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ofatumumab	-7	30 days following end of treatment	None	N/A	N/A	N/A
54	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Rituximab	-7	30 days following end of treatment	None	N/A	N/A	N/A
55	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Rituximab	-7	30 days following end of treatment	None	N/A	N/A	N/A
56	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Vincristine	-7	30 days following end of treatment	None	N/A	N/A	N/A

Appendix F: Count of Users, Episodes, Dispensings, Total Days Supplied, Years at risk, Eligible Members, Member-Years, Episodes with Events, and Number of Events by Scenario, Age Group, Sex, and Year

			Count	
Any idelalisib use, Any Indication	TOTAL	Total	Users	219
			Episodes	781
			Dispensings	781
			Days Supplied	21,274
			Amount Supplied	42,354
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
AgeGroup	18-44 Years	Users	9	
		Episodes	24	
		Dispensings	24	
		Days Supplied	673	
		Amount Supplied	1,316	
		Eligible Members	23,614,134	
		MemberYears	16,258,012.1	
AgeGroup	45-54 Years	Users	26	
		Episodes	93	
		Dispensings	93	
		Days Supplied	2,528	
		Amount Supplied	5,026	
		Eligible Members	9,304,524	
		MemberYears	6,575,969.8	
AgeGroup	55-64 Years	Users	67	
		Episodes	223	
		Dispensings	223	
		Days Supplied	5,965	
		Amount Supplied	11,864	
		Eligible Members	8,219,330	
		MemberYears	5,975,767.6	
AgeGroup	65+ Years	Users	119	
		Episodes	441	
		Dispensings	441	
		Days Supplied	12,108	
		Amount Supplied	24,148	
		Eligible Members	6,592,965	
		MemberYears	5,648,383.5	
Sex	Female	Users	96	
		Episodes	336	
		Dispensings	336	
		Days Supplied	9,272	
		Amount Supplied	18,502	
		Eligible Members	23,519,031	
		MemberYears	17,719,236.5	
Sex	Male	Users	123	
		Episodes	445	
		Dispensings	445	
		Days Supplied	12,002	
		Amount Supplied	23,852	
		Eligible Members	22,416,713	
		MemberYears	16,737,341.4	
Sex	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	2,258	
		MemberYears	1,555.1	

Year	2014	Users	99
		Episodes	212
		Dispensings	212
		Days Supplied	6,064
		Amount Supplied	12,068
		Eligible Members	37,580,728
		MemberYears	14,924,033.6
	2015	Users	169
		Episodes	569
		Dispensings	569
		Days Supplied	15,210
		Amount Supplied	30,286
		Eligible Members	38,386,167
		MemberYears	19,534,099.5
Any idelalisib use, CLL	TOTAL	Total	
		Users	105
		Episodes	405
		Dispensings	405
		Days Supplied	10,931
		Amount Supplied	21,890
		Eligible Members	37,389
		MemberYears	29,277.0
	AgeGroup	18-44 Years	
		Users	2
		Episodes	10
		Dispensings	10
		Days Supplied	279
		Amount Supplied	558
		Eligible Members	1,028
		MemberYears	594.0
		45-54 Years	
		Users	5
		Episodes	10
		Dispensings	10
		Days Supplied	282
		Amount Supplied	564
		Eligible Members	3,173
		MemberYears	2,063.2
		55-64 Years	
		Users	38
		Episodes	127
		Dispensings	127
		Days Supplied	3,416
		Amount Supplied	6,832
		Eligible Members	9,262
		MemberYears	6,462.2
		65+ Years	
		Users	62
		Episodes	258
		Dispensings	258
		Days Supplied	6,954
		Amount Supplied	13,936
		Eligible Members	25,103
		MemberYears	20,157.5
	Sex	Female	
		Users	40
		Episodes	164
		Dispensings	164
		Days Supplied	4,529
		Amount Supplied	9,086
		Eligible Members	15,900
		MemberYears	12,461.7
		Male	
		Users	65
		Episodes	241
		Dispensings	241
		Days Supplied	6,402
		Amount Supplied	12,804
		Eligible Members	21,487
		MemberYears	16,814.0

Unknown			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
Year	2014		Users	47
			Episodes	106
			Dispensings	106
			Days Supplied	3,061
			Amount Supplied	6,122
			Eligible Members	32,634
			MemberYears	12,875.6
	2015		Users	84
			Episodes	299
			Dispensings	299
			Days Supplied	7,870
			Amount Supplied	15,768
			Eligible Members	31,284
			MemberYears	16,401.4
Indication	TOTAL	Total	Users	9
Idelalisib and Bendamustine, Any			Episodes	9
			Dispensings	9
			Days Supplied	452
			Amount Supplied	8
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
AgeGroup	18-44 Years		Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
	45-54 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
	55-64 Years		Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	222
			Amount Supplied	4
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
	65+ Years		Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	200
			Amount Supplied	3
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
Sex	Female		Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	136
			Amount Supplied	3
			Eligible Members	23,519,031
			MemberYears	17,719,236.5

Male			Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	316
			Amount Supplied	5
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
Unknown			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
Year	2014		Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	282
			Amount Supplied	5
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
	2015		Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	170
			Amount Supplied	3
			Eligible Members	38,386,167
			MemberYears	19,534,099.5
Idelalisib and Bendamustine, CLL	TOTAL	Total	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	37,389
			MemberYears	29,277.0
AgeGroup	18-44 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	1,028
			MemberYears	594.0
	45-54 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,173
			MemberYears	2,063.2
	55-64 Years		Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	9,262
			MemberYears	6,462.2
	65+ Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	25,103
			MemberYears	20,157.5

Sex	Female	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	15,900	
		MemberYears	12,461.7	
Male	Users	1		
	Episodes	1		
	Dispensings	1		
	Days Supplied	30		
	Amount Supplied	1		
	Eligible Members	21,487		
	MemberYears	16,814.0		
Unknown	Users	0		
	Episodes	0		
	Dispensings	0		
	Days Supplied	0		
	Amount Supplied	0		
	Eligible Members	2		
	MemberYears	1.3		
Year	2014	Users	1	
		Episodes	1	
		Dispensings	1	
		Days Supplied	30	
		Amount Supplied	1	
		Eligible Members	32,634	
		MemberYears	12,875.6	
2015	Users	0		
	Episodes	0		
	Dispensings	0		
	Days Supplied	0		
	Amount Supplied	0		
	Eligible Members	31,284		
	MemberYears	16,401.4		
Idelalisib and Bortezomib, Any Indication	TOTAL	Total	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	60
			Amount Supplied	2
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
Days Supplied			0	
Amount Supplied			0	
Eligible Members			23,614,134	
MemberYears			16,258,012.1	
45-54 Years	Users	0		
	Episodes	0		
	Dispensings	0		
	Days Supplied	0		
	Amount Supplied	0		
	Eligible Members	9,304,524		
	MemberYears	6,575,969.8		
55-64 Years	Users	2		
	Episodes	2		
	Dispensings	2		
	Days Supplied	60		
	Amount Supplied	2		
	Eligible Members	8,219,330		
	MemberYears	5,975,767.6		
65+ Years	Users	0		

		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	6,592,965
		MemberYears	5,648,383.5
	Sex	Female	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	23,519,031
		MemberYears	17,719,236.5
		Male	
		Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	60
		Amount Supplied	2
		Eligible Members	22,416,713
		MemberYears	16,737,341.4
		Unknown	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	2,258
		MemberYears	1,555.1
	Year	2014	
		Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	60
		Amount Supplied	2
		Eligible Members	37,580,728
		MemberYears	14,924,033.6
		2015	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	38,386,167
		MemberYears	19,534,099.5
Idelalisib and Bortezomib, CLL	TOTAL	Total	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	37,389
		MemberYears	29,277.0
	AgeGroup	18-44 Years	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	1,028
		MemberYears	594.0
		45-54 Years	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	3,173
		MemberYears	2,063.2

55-64 Years			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,262
			MemberYears	6,462.2
65+ Years			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	25,103
			MemberYears	20,157.5
Sex	Female		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	15,900
			MemberYears	12,461.7
	Male		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	21,487
			MemberYears	16,814.0
	Unknown		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
Year	2014		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	32,634
			MemberYears	12,875.6
	2015		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	31,284
			MemberYears	16,401.4
Indication	TOTAL	Total	Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	195
			Amount Supplied	4
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
		45-54 Years	Users	0

		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	9,304,524	
		MemberYears	6,575,969.8	
	55-64 Years	Users	4	
		Episodes	4	
		Dispensings	4	
		Days Supplied	165	
		Amount Supplied	3	
		Eligible Members	8,219,330	
		MemberYears	5,975,767.6	
	65+ Years	Users	1	
		Episodes	1	
		Dispensings	1	
		Days Supplied	30	
		Amount Supplied	1	
		Eligible Members	6,592,965	
		MemberYears	5,648,383.5	
	Sex Female	Users	2	
		Episodes	2	
		Dispensings	2	
		Days Supplied	122	
		Amount Supplied	2	
		Eligible Members	23,519,031	
		MemberYears	17,719,236.5	
	Male	Users	3	
		Episodes	3	
		Dispensings	3	
		Days Supplied	73	
		Amount Supplied	2	
		Eligible Members	22,416,713	
		MemberYears	16,737,341.4	
	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	2,258	
		MemberYears	1,555.1	
	Year 2014	Users	3	
		Episodes	3	
		Dispensings	3	
		Days Supplied	152	
		Amount Supplied	3	
		Eligible Members	37,580,728	
		MemberYears	14,924,033.6	
	2015	Users	2	
		Episodes	2	
		Dispensings	2	
		Days Supplied	43	
		Amount Supplied	1	
		Eligible Members	38,386,167	
		MemberYears	19,534,099.5	
Idelalisib and Chlorambucil, CLL	TOTAL	Total	Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	195
			Amount Supplied	4
			Eligible Members	37,389
			MemberYears	29,277.0

AgeGroup	18-44 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	1,028
		MemberYears	594.0
45-54 Years	Users	0	
	Episodes	0	
	Dispensings	0	
	Days Supplied	0	
	Amount Supplied	0	
	Eligible Members	3,173	
	MemberYears	2,063.2	
55-64 Years	Users	4	
	Episodes	4	
	Dispensings	4	
	Days Supplied	165	
	Amount Supplied	3	
	Eligible Members	9,262	
	MemberYears	6,462.2	
65+ Years	Users	1	
	Episodes	1	
	Dispensings	1	
	Days Supplied	30	
	Amount Supplied	1	
	Eligible Members	25,103	
	MemberYears	20,157.5	
Sex	Female	Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	122
		Amount Supplied	2
		Eligible Members	15,900
		MemberYears	12,461.7
Male	Users	3	
	Episodes	3	
	Dispensings	3	
	Days Supplied	73	
	Amount Supplied	2	
	Eligible Members	21,487	
	MemberYears	16,814.0	
Unknown	Users	0	
	Episodes	0	
	Dispensings	0	
	Days Supplied	0	
	Amount Supplied	0	
	Eligible Members	2	
	MemberYears	1.3	
Year	2014	Users	3
		Episodes	3
		Dispensings	3
		Days Supplied	152
		Amount Supplied	3
		Eligible Members	32,634
		MemberYears	12,875.6
2015	Users	2	
	Episodes	2	
	Dispensings	2	
	Days Supplied	43	
	Amount Supplied	1	
	Eligible Members	31,284	
	MemberYears	16,401.4	
Idelalisib and Cyclophosphamide, Any Indication		TOTAL	Total
		Users	2

		Episodes	2
		Dispensings	2
		Days Supplied	294
		Amount Supplied	2
		Eligible Members	45,938,002
		MemberYears	34,458,133.1
	AgeGroup 18-44 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	23,614,134
		MemberYears	16,258,012.1
	45-54 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	9,304,524
		MemberYears	6,575,969.8
	55-64 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	8,219,330
		MemberYears	5,975,767.6
	65+ Years	Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	294
		Amount Supplied	2
		Eligible Members	6,592,965
		MemberYears	5,648,383.5
	Sex Female	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	267
		Amount Supplied	1
		Eligible Members	23,519,031
		MemberYears	17,719,236.5
	Male	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	27
		Amount Supplied	1
		Eligible Members	22,416,713
		MemberYears	16,737,341.4
	Unknown	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	2,258
		MemberYears	1,555.1
	Year 2014	Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	294
		Amount Supplied	2
		Eligible Members	37,580,728
		MemberYears	14,924,033.6
	2015	Users	0
		Episodes	0
		Dispensings	0

			Days Supplied	0
			Amount Supplied	0
			Eligible Members	38,386,167
			MemberYears	19,534,099.5
Idelalisib and Cyclophosphamide, CLL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	1,028
			MemberYears	594.0
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,173
			MemberYears	2,063.2
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	25,103
			MemberYears	20,157.5
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	21,487
			MemberYears	16,814.0
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0

			Amount Supplied	0
			Eligible Members	32,634
			MemberYears	12,875.6
	2015		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Doxorubicin, Any Indication	TOTAL	Total	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
		55-64 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	23,519,031
			MemberYears	17,719,236.5
		Male	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0

		Eligible Members	2,258
		MemberYears	1,555.1
Year	2014	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	30
		Amount Supplied	1
		Eligible Members	37,580,728
		MemberYears	14,924,033.6
	2015	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	38,386,167
		MemberYears	19,534,099.5
Idelalisib and Doxorubicin, CLL	TOTAL	Total	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	37,389
		MemberYears	29,277.0
AgeGroup	18-44 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	1,028
		MemberYears	594.0
	45-54 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	3,173
		MemberYears	2,063.2
	55-64 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	9,262
		MemberYears	6,462.2
	65+ Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	25,103
		MemberYears	20,157.5
Sex	Female	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	15,900
		MemberYears	12,461.7

Male			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	21,487
			MemberYears	16,814.0
Unknown			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
Year	2014		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	32,634
			MemberYears	12,875.6
	2015		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Ibritumomab, Any Indication	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
AgeGroup	18-44 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
	45-54 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
	55-64 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
	65+ Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
Sex	Female		Users	0

		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	23,519,031	
		MemberYears	17,719,236.5	
	Male	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	22,416,713	
		MemberYears	16,737,341.4	
	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	2,258	
		MemberYears	1,555.1	
	Year 2014	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	37,580,728	
		MemberYears	14,924,033.6	
	2015	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	38,386,167	
		MemberYears	19,534,099.5	
Idelalisib and Ibritumomab, CLL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup 18-44 Years	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	1,028	
		MemberYears	594.0	
	45-54 Years	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	3,173	
		MemberYears	2,063.2	
	55-64 Years	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	9,262	
		MemberYears	6,462.2	

65+ Years			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	25,103
			MemberYears	20,157.5
Sex	Female		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	15,900
			MemberYears	12,461.7
	Male		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	21,487
			MemberYears	16,814.0
	Unknown		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
Year	2014		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	32,634
			MemberYears	12,875.6
	2015		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Ibrutinib, Any Indication	TOTAL	Total	Users	21
			Episodes	21
			Dispensings	21
			Days Supplied	1,662
			Amount Supplied	18
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	182
			Amount Supplied	2
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
		45-54 Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	60
			Amount Supplied	2
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
		55-64 Years	Users	8

		Episodes	8	
		Dispensings	8	
		Days Supplied	350	
		Amount Supplied	7	
		Eligible Members	8,219,330	
		MemberYears	5,975,767.6	
	65+ Years	Users	9	
		Episodes	9	
		Dispensings	9	
		Days Supplied	1,070	
		Amount Supplied	8	
		Eligible Members	6,592,965	
		MemberYears	5,648,383.5	
	Sex Female	Users	7	
		Episodes	7	
		Dispensings	7	
		Days Supplied	975	
		Amount Supplied	6	
		Eligible Members	23,519,031	
		MemberYears	17,719,236.5	
	Male	Users	14	
		Episodes	14	
		Dispensings	14	
		Days Supplied	687	
		Amount Supplied	12	
		Eligible Members	22,416,713	
		MemberYears	16,737,341.4	
	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	2,258	
		MemberYears	1,555.1	
	Year 2014	Users	15	
		Episodes	15	
		Dispensings	15	
		Days Supplied	1,370	
		Amount Supplied	14	
		Eligible Members	37,580,728	
		MemberYears	14,924,033.6	
	2015	Users	6	
		Episodes	6	
		Dispensings	6	
		Days Supplied	292	
		Amount Supplied	4	
		Eligible Members	38,386,167	
		MemberYears	19,534,099.5	
Idelalisib and Ibrutinib, CLL	TOTAL	Total	Users	15
			Episodes	15
			Dispensings	15
			Days Supplied	983
			Amount Supplied	13
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	1,028
			MemberYears	594.0

45-54 Years			Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	60
			Amount Supplied	2
			Eligible Members	3,173
			MemberYears	2,063.2
55-64 Years			Users	6
			Episodes	6
			Dispensings	6
			Days Supplied	260
			Amount Supplied	5
			Eligible Members	9,262
			MemberYears	6,462.2
65+ Years			Users	7
			Episodes	7
			Dispensings	7
			Days Supplied	663
			Amount Supplied	6
			Eligible Members	25,103
			MemberYears	20,157.5
Sex	Female		Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	416
			Amount Supplied	4
			Eligible Members	15,900
			MemberYears	12,461.7
	Male		Users	11
			Episodes	11
			Dispensings	11
			Days Supplied	567
			Amount Supplied	9
			Eligible Members	21,487
			MemberYears	16,814.0
	Unknown		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
Year	2014		Users	9
			Episodes	9
			Dispensings	9
			Days Supplied	691
			Amount Supplied	9
			Eligible Members	32,634
			MemberYears	12,875.6
	2015		Users	6
			Episodes	6
			Dispensings	6
			Days Supplied	292
			Amount Supplied	4
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Lenalidomide, Any Indication			Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	311
			Amount Supplied	5
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
AgeGroup	18-44 Years		Users	1

		Episodes	1
		Dispensings	1
		Days Supplied	30
		Amount Supplied	1
		Eligible Members	23,614,134
		MemberYears	16,258,012.1
	45-54 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	9,304,524
		MemberYears	6,575,969.8
	55-64 Years	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	30
		Amount Supplied	1
		Eligible Members	8,219,330
		MemberYears	5,975,767.6
	65+ Years	Users	3
		Episodes	3
		Dispensings	3
		Days Supplied	251
		Amount Supplied	3
		Eligible Members	6,592,965
		MemberYears	5,648,383.5
Sex	Female	Users	3
		Episodes	3
		Dispensings	3
		Days Supplied	251
		Amount Supplied	3
		Eligible Members	23,519,031
		MemberYears	17,719,236.5
	Male	Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	60
		Amount Supplied	2
		Eligible Members	22,416,713
		MemberYears	16,737,341.4
	Unknown	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	2,258
		MemberYears	1,555.1
Year	2014	Users	4
		Episodes	4
		Dispensings	4
		Days Supplied	212
		Amount Supplied	4
		Eligible Members	37,580,728
		MemberYears	14,924,033.6
	2015	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	99
		Amount Supplied	1
		Eligible Members	38,386,167
		MemberYears	19,534,099.5

Idelalisib and Lenalidomide, CLL	TOTAL	Total		
			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	1,028
			MemberYears	594.0
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,173
			MemberYears	2,063.2
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	25,103
			MemberYears	20,157.5
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	21,487
			MemberYears	16,814.0
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	32,634
			MemberYears	12,875.6

2015			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Obinutuzumab, Any Indication			Users	4
TOTAL			Episodes	4
Total			Dispensings	4
			Days Supplied	908
			Amount Supplied	4
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
AgeGroup 18-44 Years			Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	152
			Amount Supplied	1
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
45-54 Years			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
55-64 Years			Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	133
			Amount Supplied	1
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
65+ Years			Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	623
			Amount Supplied	2
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
Sex Female			Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	362
			Amount Supplied	2
			Eligible Members	23,519,031
			MemberYears	17,719,236.5
Male			Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	546
			Amount Supplied	2
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
Unknown			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
Year 2014			Users	3

		Episodes	3	
		Dispensings	3	
		Days Supplied	775	
		Amount Supplied	3	
		Eligible Members	37,580,728	
		MemberYears	14,924,033.6	
	2015	Users	1	
		Episodes	1	
		Dispensings	1	
		Days Supplied	133	
		Amount Supplied	1	
		Eligible Members	38,386,167	
		MemberYears	19,534,099.5	
Idelalisib and Obinutuzumab, CLL	TOTAL	Total	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	756
			Amount Supplied	3
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	1,028
			MemberYears	594.0
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,173
			MemberYears	2,063.2
		55-64 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	133
			Amount Supplied	1
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	623
			Amount Supplied	2
			Eligible Members	25,103
			MemberYears	20,157.5
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	210
			Amount Supplied	1
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	546
			Amount Supplied	2
			Eligible Members	21,487
			MemberYears	16,814.0

Unknown			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
Year	2014			
			Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	623
			Amount Supplied	2
			Eligible Members	32,634
			MemberYears	12,875.6
2015				
			Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	133
			Amount Supplied	1
			Eligible Members	31,284
			MemberYears	16,401.4
Indication	TOTAL	Total		
Idelalisib and Ofatumumab, Any			Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	379
			Amount Supplied	2
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
AgeGroup	18-44 Years			
			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
45-54 Years				
			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
55-64 Years				
			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
65+ Years				
			Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	379
			Amount Supplied	2
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
Sex	Female			
			Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	142
			Amount Supplied	1
			Eligible Members	23,519,031
			MemberYears	17,719,236.5
Male				
			Users	1

			Episodes	1
			Dispensings	1
			Days Supplied	237
			Amount Supplied	1
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
	Year	2014	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	379
			Amount Supplied	2
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	38,386,167
			MemberYears	19,534,099.5
Idelalisib and Ofatumumab, CLL	TOTAL	Total	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	379
			Amount Supplied	2
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	1,028
			MemberYears	594.0
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,173
			MemberYears	2,063.2
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	379
			Amount Supplied	2
			Eligible Members	25,103
			MemberYears	20,157.5

Sex	Female		
		Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	142
		Amount Supplied	1
		Eligible Members	15,900
		MemberYears	12,461.7
	Male		
		Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	237
		Amount Supplied	1
		Eligible Members	21,487
		MemberYears	16,814.0
	Unknown		
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	2
		MemberYears	1.3
Year	2014		
		Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	379
		Amount Supplied	2
		Eligible Members	32,634
		MemberYears	12,875.6
	2015		
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	31,284
		MemberYears	16,401.4
Indication	TOTAL	Total	
Idelalisib and Prednisone, Any			Users
			46
			Episodes
			47
			Dispensings
			47
			Days Supplied
			5,698
			Amount Supplied
			42
			Eligible Members
			45,938,002
			MemberYears
			34,458,133.1
AgeGroup	18-44 Years		
		Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	327
		Amount Supplied	2
		Eligible Members	23,614,134
		MemberYears	16,258,012.1
	45-54 Years		
		Users	3
		Episodes	3
		Dispensings	3
		Days Supplied	462
		Amount Supplied	3
		Eligible Members	9,304,524
		MemberYears	6,575,969.8
	55-64 Years		
		Users	17
		Episodes	17
		Dispensings	17
		Days Supplied	1,719
		Amount Supplied	15
		Eligible Members	8,219,330
		MemberYears	5,975,767.6
	65+ Years		
		Users	24

		Episodes	25
		Dispensings	25
		Days Supplied	3,190
		Amount Supplied	23
		Eligible Members	6,592,965
		MemberYears	5,648,383.5
	Sex	Female	Users
			17
		Episodes	18
		Dispensings	18
		Days Supplied	2,320
		Amount Supplied	16
		Eligible Members	23,519,031
		MemberYears	17,719,236.5
		Male	Users
			29
		Episodes	29
		Dispensings	29
		Days Supplied	3,378
		Amount Supplied	26
		Eligible Members	22,416,713
		MemberYears	16,737,341.4
		Unknown	Users
			0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	2,258
		MemberYears	1,555.1
	Year	2014	Users
			20
		Episodes	20
		Dispensings	20
		Days Supplied	3,089
		Amount Supplied	19
		Eligible Members	37,580,728
		MemberYears	14,924,033.6
		2015	Users
			26
		Episodes	27
		Dispensings	27
		Days Supplied	2,609
		Amount Supplied	22
		Eligible Members	38,386,167
		MemberYears	19,534,099.5
Idelalisib and Prednisone, CLL	TOTAL	Total	Users
			29
			Episodes
			29
			Dispensings
			29
			Days Supplied
			3,622
			Amount Supplied
			26
			Eligible Members
			37,389
			MemberYears
			29,277.0
	AgeGroup	18-44 Years	Users
			1
			Episodes
			1
			Dispensings
			1
			Days Supplied
			175
			Amount Supplied
			1
			Eligible Members
			1,028
			MemberYears
			594.0
		45-54 Years	Users
			1
			Episodes
			1
			Dispensings
			1
			Days Supplied
			218
			Amount Supplied
			1
			Eligible Members
			3,173
			MemberYears
			2,063.2

55-64 Years			Users	12
			Episodes	12
			Dispensings	12
			Days Supplied	1,036
			Amount Supplied	10
			Eligible Members	9,262
			MemberYears	6,462.2
65+ Years			Users	15
			Episodes	15
			Dispensings	15
			Days Supplied	2,193
			Amount Supplied	14
			Eligible Members	25,103
			MemberYears	20,157.5
Sex	Female		Users	8
			Episodes	8
			Dispensings	8
			Days Supplied	1,267
			Amount Supplied	8
			Eligible Members	15,900
			MemberYears	12,461.7
	Male		Users	21
			Episodes	21
			Dispensings	21
			Days Supplied	2,355
			Amount Supplied	18
			Eligible Members	21,487
			MemberYears	16,814.0
	Unknown		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
Year	2014		Users	11
			Episodes	11
			Dispensings	11
			Days Supplied	1,665
			Amount Supplied	11
			Eligible Members	32,634
			MemberYears	12,875.6
	2015		Users	18
			Episodes	18
			Dispensings	18
			Days Supplied	1,957
			Amount Supplied	15
			Eligible Members	31,284
			MemberYears	16,401.4
Indication	TOTAL	Total	Users	81
			Episodes	85
			Dispensings	85
			Days Supplied	9,625
			Amount Supplied	79
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	129
			Amount Supplied	2
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
	45-54 Years		Users	8

		Episodes	8	
		Dispensings	8	
		Days Supplied	940	
		Amount Supplied	8	
		Eligible Members	9,304,524	
		MemberYears	6,575,969.8	
	55-64 Years	Users	24	
		Episodes	25	
		Dispensings	25	
		Days Supplied	2,889	
		Amount Supplied	23	
		Eligible Members	8,219,330	
		MemberYears	5,975,767.6	
	65+ Years	Users	47	
		Episodes	50	
		Dispensings	50	
		Days Supplied	5,667	
		Amount Supplied	46	
		Eligible Members	6,592,965	
		MemberYears	5,648,383.5	
	Sex Female	Users	29	
		Episodes	29	
		Dispensings	29	
		Days Supplied	3,678	
		Amount Supplied	28	
		Eligible Members	23,519,031	
		MemberYears	17,719,236.5	
	Male	Users	52	
		Episodes	56	
		Dispensings	56	
		Days Supplied	5,947	
		Amount Supplied	51	
		Eligible Members	22,416,713	
		MemberYears	16,737,341.4	
	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	2,258	
		MemberYears	1,555.1	
	Year 2014	Users	42	
		Episodes	42	
		Dispensings	42	
		Days Supplied	5,629	
		Amount Supplied	41	
		Eligible Members	37,580,728	
		MemberYears	14,924,033.6	
	2015	Users	41	
		Episodes	43	
		Dispensings	43	
		Days Supplied	3,996	
		Amount Supplied	38	
		Eligible Members	38,386,167	
		MemberYears	19,534,099.5	
Idelalisib and Rituximab, CLL	TOTAL	Total	Users	51
			Episodes	55
			Dispensings	55
			Days Supplied	6,623
			Amount Supplied	50
			Eligible Members	37,389
			MemberYears	29,277.0

AgeGroup	18-44 Years	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	1,028	
		MemberYears	594.0	
		45-54 Years	Users	2
Episodes	2			
Dispensings	2			
Days Supplied	248			
Amount Supplied	2			
Eligible Members	3,173			
MemberYears	2,063.2			
55-64 Years	Users		18	
	Episodes	19		
	Dispensings	19		
	Days Supplied	2,267		
	Amount Supplied	17		
	Eligible Members	9,262		
	MemberYears	6,462.2		
	65+ Years	Users	31	
Episodes		34		
Dispensings		34		
Days Supplied		4,108		
Amount Supplied		31		
Eligible Members		25,103		
MemberYears		20,157.5		
Sex		Female	Users	19
	Episodes		19	
	Dispensings		19	
	Days Supplied		2,518	
	Amount Supplied		18	
	Eligible Members		15,900	
	MemberYears		12,461.7	
	Male		Users	32
Episodes		36		
Dispensings		36		
Days Supplied		4,105		
Amount Supplied		32		
Eligible Members		21,487		
MemberYears		16,814.0		
Unknown		Users	0	
	Episodes	0		
	Dispensings	0		
	Days Supplied	0		
	Amount Supplied	0		
	Eligible Members	2		
	MemberYears	1.3		
	Year	2014	Users	25
Episodes			25	
Dispensings			25	
Days Supplied			3,668	
Amount Supplied			24	
Eligible Members			32,634	
MemberYears			12,875.6	
2015			Users	28
	Episodes	30		
	Dispensings	30		
	Days Supplied	2,955		
	Amount Supplied	26		
	Eligible Members	31,284		
	MemberYears	16,401.4		
	Idelalisib and Vincristine, Any Indication	TOTAL	Total	Users

		Episodes	1	
		Dispensings	1	
		Days Supplied	267	
		Amount Supplied	1	
		Eligible Members	45,938,002	
		MemberYears	34,458,133.1	
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
		65+ Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	267
			Amount Supplied	1
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	267
			Amount Supplied	1
			Eligible Members	23,519,031
			MemberYears	17,719,236.5
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
	Year	2014	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	267
			Amount Supplied	1
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
		2015	Users	0
			Episodes	0
			Dispensings	0

		Days Supplied	0
		Amount Supplied	0
		Eligible Members	38,386,167
		MemberYears	19,534,099.5
Idelalisib and Vincristine, CLL	TOTAL	Total	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	37,389
		MemberYears	29,277.0
	AgeGroup	18-44 Years	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	1,028
		MemberYears	594.0
		45-54 Years	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	3,173
		MemberYears	2,063.2
		55-64 Years	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	9,262
		MemberYears	6,462.2
		65+ Years	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	25,103
		MemberYears	20,157.5
	Sex	Female	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	15,900
		MemberYears	12,461.7
		Male	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	21,487
		MemberYears	16,814.0
		Unknown	
		Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	2
		MemberYears	1.3

Year	2014	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	32,634
		MemberYears	12,875.6
	2015	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	31,284
		MemberYears	16,401.4
Any idelalisib use, FL	TOTAL	Total	
		Users	82
		Episodes	278
		Dispensings	278
		Days Supplied	7,757
		Amount Supplied	15,332
		Eligible Members	22,182
		MemberYears	15,238.4
	AgeGroup	18-44 Years	
		Users	5
		Episodes	9
		Dispensings	9
		Days Supplied	244
		Amount Supplied	488
		Eligible Members	2,015
		MemberYears	1,195.7
		45-54 Years	
		Users	15
		Episodes	59
		Dispensings	59
		Days Supplied	1,615
		Amount Supplied	3,200
		Eligible Members	3,545
		MemberYears	2,217.5
		55-64 Years	
		Users	18
		Episodes	74
		Dispensings	74
		Days Supplied	1,944
		Amount Supplied	3,832
		Eligible Members	6,511
		MemberYears	4,249.9
		65+ Years	
		Users	44
		Episodes	136
		Dispensings	136
		Days Supplied	3,954
		Amount Supplied	7,812
		Eligible Members	10,917
		MemberYears	7,575.3
	Sex	Female	
		Users	38
		Episodes	121
		Dispensings	121
		Days Supplied	3,380
		Amount Supplied	6,730
		Eligible Members	11,031
		MemberYears	7,610.8
		Male	
		Users	44
		Episodes	157
		Dispensings	157
		Days Supplied	4,377
		Amount Supplied	8,602
		Eligible Members	11,151
		MemberYears	7,627.6

Unknown		Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	0	
		MemberYears	0.0	
Year	2014	Users	43	
		Episodes	91	
		Dispensings	91	
		Days Supplied	2,614	
		Amount Supplied	5,198	
		Eligible Members	19,019	
		MemberYears	7,024.3	
	2015	Users	58	
		Episodes	187	
		Dispensings	187	
		Days Supplied	5,143	
		Amount Supplied	10,134	
		Eligible Members	17,326	
		MemberYears	8,214.2	
Any idelalisib, SLL	TOTAL	Total	Users	171
			Episodes	575
			Dispensings	575
			Days Supplied	15,782
			Amount Supplied	31,342
			Eligible Members	86,698
			MemberYears	60,976.1
AgeGroup	18-44 Years	Users	7	
		Episodes	13	
		Dispensings	13	
		Days Supplied	364	
		Amount Supplied	698	
		Eligible Members	11,206	
		MemberYears	6,918.1	
	45-54 Years	Users	25	
		Episodes	90	
		Dispensings	90	
		Days Supplied	2,452	
		Amount Supplied	4,874	
		Eligible Members	12,933	
		MemberYears	8,140.3	
	55-64 Years	Users	48	
		Episodes	165	
		Dispensings	165	
		Days Supplied	4,515	
		Amount Supplied	8,964	
		Eligible Members	22,742	
		MemberYears	14,936.2	
	65+ Years	Users	92	
		Episodes	307	
		Dispensings	307	
		Days Supplied	8,451	
		Amount Supplied	16,806	
		Eligible Members	42,871	
		MemberYears	30,981.4	
Sex	Female	Users	74	
		Episodes	235	
		Dispensings	235	
		Days Supplied	6,502	
		Amount Supplied	12,934	
		Eligible Members	41,121	
		MemberYears	29,089.2	

Male			Users	97
			Episodes	340
			Dispensings	340
			Days Supplied	9,280
			Amount Supplied	18,408
			Eligible Members	45,573
			MemberYears	31,884.3
Unknown			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
Year	2014		Users	83
			Episodes	172
			Dispensings	172
			Days Supplied	4,940
			Amount Supplied	9,820
			Eligible Members	74,416
			MemberYears	27,766.1
	2015		Users	126
			Episodes	403
			Dispensings	403
			Days Supplied	10,842
			Amount Supplied	21,522
			Eligible Members	68,805
			MemberYears	33,210.0
Idelalisib and Bendamustine, FL	TOTAL	Total	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	286
			Amount Supplied	3
			Eligible Members	22,182
			MemberYears	15,238.4
AgeGroup	18-44 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
	45-54 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5
	55-64 Years		Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	132
			Amount Supplied	1
			Eligible Members	6,511
			MemberYears	4,249.9
	65+ Years		Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	154
			Amount Supplied	2
			Eligible Members	10,917
			MemberYears	7,575.3

Sex	Female	Users	1	
		Episodes	1	
		Dispensings	1	
		Days Supplied	60	
		Amount Supplied	1	
		Eligible Members	11,031	
		MemberYears	7,610.8	
	Male	Users	2	
		Episodes	2	
		Dispensings	2	
		Days Supplied	226	
		Amount Supplied	2	
		Eligible Members	11,151	
		MemberYears	7,627.6	
	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	0	
		MemberYears	0.0	
Year	2014	Users	2	
		Episodes	2	
		Dispensings	2	
		Days Supplied	192	
		Amount Supplied	2	
		Eligible Members	19,019	
		MemberYears	7,024.3	
	2015	Users	1	
		Episodes	1	
		Dispensings	1	
		Days Supplied	94	
		Amount Supplied	1	
		Eligible Members	17,326	
		MemberYears	8,214.2	
Idelalisib and Bendamustine, SLL	TOTAL	Total	Users	7
			Episodes	7
			Dispensings	7
			Days Supplied	392
			Amount Supplied	6
			Eligible Members	86,698
			MemberYears	60,976.1
	AgeGroup	18-44 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	11,206
			MemberYears	6,918.1
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,933
			MemberYears	8,140.3
		55-64 Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	162
			Amount Supplied	2
			Eligible Members	22,742
			MemberYears	14,936.2

65+ Years			Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	200
			Amount Supplied	3
			Eligible Members	42,871
			MemberYears	30,981.4
Sex	Female		Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	106
			Amount Supplied	2
			Eligible Members	41,121
			MemberYears	29,089.2
	Male		Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	286
			Amount Supplied	4
			Eligible Members	45,573
			MemberYears	31,884.3
	Unknown		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
Year	2014		Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	252
			Amount Supplied	4
			Eligible Members	74,416
			MemberYears	27,766.1
	2015		Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	140
			Amount Supplied	2
			Eligible Members	68,805
			MemberYears	33,210.0
Idelalisib and Bortezomib, FL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5

55-64 Years			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
65+ Years			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	10,917
			MemberYears	7,575.3
Sex	Female		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,031
			MemberYears	7,610.8
	Male		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,151
			MemberYears	7,627.6
	Unknown		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
Year	2014		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	19,019
			MemberYears	7,024.3
	2015		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Bortezomib, SLL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	86,698
			MemberYears	60,976.1
AgeGroup	18-44 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,206
			MemberYears	6,918.1

45-54 Years		Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	12,933	
		MemberYears	8,140.3	
55-64 Years		Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	22,742	
		MemberYears	14,936.2	
65+ Years		Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	42,871	
		MemberYears	30,981.4	
Sex	Female	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	41,121	
		MemberYears	29,089.2	
	Male	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	45,573	
		MemberYears	31,884.3	
	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	4	
		MemberYears	2.6	
Year	2014	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	74,416	
		MemberYears	27,766.1	
	2015	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	68,805	
		MemberYears	33,210.0	
Idelalisib and Chlorambucil, FL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,182
			MemberYears	15,238.4

AgeGroup	18-44 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	2,015
		MemberYears	1,195.7
45-54 Years	Users	0	
	Episodes	0	
	Dispensings	0	
	Days Supplied	0	
	Amount Supplied	0	
	Eligible Members	3,545	
	MemberYears	2,217.5	
55-64 Years	Users	0	
	Episodes	0	
	Dispensings	0	
	Days Supplied	0	
	Amount Supplied	0	
	Eligible Members	6,511	
	MemberYears	4,249.9	
65+ Years	Users	0	
	Episodes	0	
	Dispensings	0	
	Days Supplied	0	
	Amount Supplied	0	
	Eligible Members	10,917	
	MemberYears	7,575.3	
Sex	Female	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	11,031
		MemberYears	7,610.8
Male	Users	0	
	Episodes	0	
	Dispensings	0	
	Days Supplied	0	
	Amount Supplied	0	
	Eligible Members	11,151	
	MemberYears	7,627.6	
Unknown	Users	0	
	Episodes	0	
	Dispensings	0	
	Days Supplied	0	
	Amount Supplied	0	
	Eligible Members	0	
	MemberYears	0.0	
Year	2014	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	19,019
		MemberYears	7,024.3
2015	Users	0	
	Episodes	0	
	Dispensings	0	
	Days Supplied	0	
	Amount Supplied	0	
	Eligible Members	17,326	
	MemberYears	8,214.2	

Idelalisib and Chlorambucil, SLL	TOTAL	Total		
			Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	126
			Amount Supplied	2
			Eligible Members	86,698
			MemberYears	60,976.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,206
			MemberYears	6,918.1
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,933
			MemberYears	8,140.3
		55-64 Years	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	126
			Amount Supplied	2
			Eligible Members	22,742
			MemberYears	14,936.2
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	42,871
			MemberYears	30,981.4
	Sex	Female	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	122
			Amount Supplied	2
			Eligible Members	41,121
			MemberYears	29,089.2
		Male	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	4
			Amount Supplied	0
			Eligible Members	45,573
			MemberYears	31,884.3
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	122
			Amount Supplied	2
			Eligible Members	74,416
			MemberYears	27,766.1

2015		Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	4
		Amount Supplied	0
		Eligible Members	68,805
		MemberYears	33,210.0
Idelalisib and Cyclophosphamide, FL TOTAL Total		Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	27
		Amount Supplied	1
		Eligible Members	22,182
		MemberYears	15,238.4
AgeGroup	18-44 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	2,015
		MemberYears	1,195.7
	45-54 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	3,545
		MemberYears	2,217.5
	55-64 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	6,511
		MemberYears	4,249.9
	65+ Years	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	27
		Amount Supplied	1
		Eligible Members	10,917
		MemberYears	7,575.3
Sex	Female	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	11,031
		MemberYears	7,610.8
	Male	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	27
		Amount Supplied	1
		Eligible Members	11,151
		MemberYears	7,627.6
	Unknown	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	0
		MemberYears	0.0
Year	2014	Users	1

			Episodes	1
			Dispensings	1
			Days Supplied	27
			Amount Supplied	1
			Eligible Members	19,019
			MemberYears	7,024.3
	2015		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Cyclophosphamide, SLL	TOTAL	Total	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	294
			Amount Supplied	2
			Eligible Members	86,698
			MemberYears	60,976.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,206
			MemberYears	6,918.1
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,933
			MemberYears	8,140.3
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,742
			MemberYears	14,936.2
		65+ Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	294
			Amount Supplied	2
			Eligible Members	42,871
			MemberYears	30,981.4
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	267
			Amount Supplied	1
			Eligible Members	41,121
			MemberYears	29,089.2
		Male	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	27
			Amount Supplied	1
			Eligible Members	45,573
			MemberYears	31,884.3
		Unknown	Users	0
			Episodes	0

			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	294
			Amount Supplied	2
			Eligible Members	74,416
			MemberYears	27,766.1
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	68,805
			MemberYears	33,210.0
Idelalisib and Doxorubicin, FL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	10,917
			MemberYears	7,575.3
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,031
			MemberYears	7,610.8

Male			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,151
			MemberYears	7,627.6
Unknown			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
Year	2014		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	19,019
			MemberYears	7,024.3
	2015		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Doxorubicin, SLL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	86,698
			MemberYears	60,976.1
AgeGroup	18-44 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,206
			MemberYears	6,918.1
	45-54 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,933
			MemberYears	8,140.3
	55-64 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,742
			MemberYears	14,936.2
	65+ Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	42,871
			MemberYears	30,981.4

Sex	Female	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	41,121	
		MemberYears	29,089.2	
	Male	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	45,573	
		MemberYears	31,884.3	
	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	4	
		MemberYears	2.6	
Year	2014	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	74,416	
		MemberYears	27,766.1	
	2015	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	68,805	
		MemberYears	33,210.0	
Idelalisib and Ibritumomab, FL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9

65+ Years			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	10,917
			MemberYears	7,575.3
Sex	Female			
			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,031
			MemberYears	7,610.8
Male			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,151
			MemberYears	7,627.6
Unknown			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
Year	2014			
			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	19,019
			MemberYears	7,024.3
2015			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Ibritumomab, SLL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	85,326
			MemberYears	60,194.2
AgeGroup	18-44 Years			
			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,024
			MemberYears	6,821.4
45-54 Years			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,693
			MemberYears	8,015.4

55-64 Years		Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	22,307	
		MemberYears	14,698.5	
65+ Years		Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	42,310	
		MemberYears	30,658.9	
Sex	Female	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	40,483	
		MemberYears	28,725.3	
	Male	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	44,839	
		MemberYears	31,466.4	
	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	4	
		MemberYears	2.6	
Year	2014	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	73,071	
		MemberYears	27,252.3	
	2015	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	67,683	
		MemberYears	32,941.9	
Idelalisib and Ibrutinib, FL	TOTAL	Total	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	325
			Amount Supplied	2
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	2,015
			MemberYears	1,195.7

45-54 Years			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5
55-64 Years			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
65+ Years			Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	295
			Amount Supplied	1
			Eligible Members	10,917
			MemberYears	7,575.3
Sex	Female		Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	295
			Amount Supplied	1
			Eligible Members	11,031
			MemberYears	7,610.8
	Male		Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	11,151
			MemberYears	7,627.6
	Unknown		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
Year	2014		Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	325
			Amount Supplied	2
			Eligible Members	19,019
			MemberYears	7,024.3
	2015		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Ibrutinib, SLL	TOTAL	Total	Users	15
			Episodes	15
			Dispensings	15
			Days Supplied	1,220
			Amount Supplied	13
			Eligible Members	85,326
			MemberYears	60,194.2

AgeGroup	18-44 Years	Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	182
		Amount Supplied	2
		Eligible Members	11,024
		MemberYears	6,821.4
45-54 Years	45-54 Years	Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	60
		Amount Supplied	2
		Eligible Members	12,693
		MemberYears	8,015.4
55-64 Years	55-64 Years	Users	5
		Episodes	5
		Dispensings	5
		Days Supplied	203
		Amount Supplied	4
		Eligible Members	22,307
		MemberYears	14,698.5
65+ Years	65+ Years	Users	6
		Episodes	6
		Dispensings	6
		Days Supplied	775
		Amount Supplied	5
		Eligible Members	42,310
		MemberYears	30,658.9
Sex	Female	Users	6
		Episodes	6
		Dispensings	6
		Days Supplied	792
		Amount Supplied	5
		Eligible Members	40,483
		MemberYears	28,725.3
Male	Male	Users	9
		Episodes	9
		Dispensings	9
		Days Supplied	428
		Amount Supplied	8
		Eligible Members	44,839
		MemberYears	31,466.4
Unknown	Unknown	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	4
		MemberYears	2.6
Year	2014	Users	12
		Episodes	12
		Dispensings	12
		Days Supplied	1,097
		Amount Supplied	11
		Eligible Members	73,071
		MemberYears	27,252.3
2015	2015	Users	3
		Episodes	3
		Dispensings	3
		Days Supplied	123
		Amount Supplied	2
		Eligible Members	67,683
		MemberYears	32,941.9

Idelalisib and Lenalidomide, FL	TOTAL	Total		
			Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	122
			Amount Supplied	2
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
		65+ Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	92
			Amount Supplied	1
			Eligible Members	10,917
			MemberYears	7,575.3
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	92
			Amount Supplied	1
			Eligible Members	11,031
			MemberYears	7,610.8
		Male	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	11,151
			MemberYears	7,627.6
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
	Year	2014	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	122
			Amount Supplied	2
			Eligible Members	19,019
			MemberYears	7,024.3

2015			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Lenalidomide, SLL	TOTAL	Total	Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	311
			Amount Supplied	5
			Eligible Members	85,326
			MemberYears	60,194.2
AgeGroup	18-44 Years		Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	11,024
			MemberYears	6,821.4
	45-54 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,693
			MemberYears	8,015.4
	55-64 Years		Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	22,307
			MemberYears	14,698.5
	65+ Years		Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	251
			Amount Supplied	3
			Eligible Members	42,310
			MemberYears	30,658.9
Sex	Female		Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	251
			Amount Supplied	3
			Eligible Members	40,483
			MemberYears	28,725.3
	Male		Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	60
			Amount Supplied	2
			Eligible Members	44,839
			MemberYears	31,466.4
	Unknown		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6

Year	2014	Users	4
		Episodes	4
		Dispensings	4
		Days Supplied	212
		Amount Supplied	4
		Eligible Members	73,071
		MemberYears	27,252.3
	2015	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	99
		Amount Supplied	1
		Eligible Members	67,683
		MemberYears	32,941.9
Idelalisib and Obinutuzumab, FL	TOTAL	Total	
		Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	210
		Amount Supplied	1
		Eligible Members	22,182
		MemberYears	15,238.4
AgeGroup	18-44 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	2,015
		MemberYears	1,195.7
	45-54 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	3,545
		MemberYears	2,217.5
	55-64 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	6,511
		MemberYears	4,249.9
	65+ Years	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	210
		Amount Supplied	1
		Eligible Members	10,917
		MemberYears	7,575.3
Sex	Female	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	210
		Amount Supplied	1
		Eligible Members	11,031
		MemberYears	7,610.8
	Male	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	11,151
		MemberYears	7,627.6

Unknown		Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	0	
		MemberYears	0.0	
Year	2014	Users	1	
		Episodes	1	
		Dispensings	1	
		Days Supplied	210	
		Amount Supplied	1	
		Eligible Members	19,019	
		MemberYears	7,024.3	
	2015	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	17,326	
		MemberYears	8,214.2	
Idelalisib and Obinutuzumab, SLL	TOTAL	Total	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	775
			Amount Supplied	3
			Eligible Members	85,326
			MemberYears	60,194.2
	AgeGroup	18-44 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	152
			Amount Supplied	1
			Eligible Members	11,024
			MemberYears	6,821.4
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,693
			MemberYears	8,015.4
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,307
			MemberYears	14,698.5
		65+ Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	623
			Amount Supplied	2
			Eligible Members	42,310
			MemberYears	30,658.9
	Sex	Female	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	362
			Amount Supplied	2
			Eligible Members	40,483
			MemberYears	28,725.3

Male			Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	413
			Amount Supplied	1
			Eligible Members	44,839
			MemberYears	31,466.4
Unknown			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
Year	2014		Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	775
			Amount Supplied	3
			Eligible Members	73,071
			MemberYears	27,252.3
	2015		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	67,683
			MemberYears	32,941.9
Idelalisib and Ofatumumab, FL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,182
			MemberYears	15,238.4
AgeGroup	18-44 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
	45-54 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5
	55-64 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
	65+ Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	10,917
			MemberYears	7,575.3

Sex	Female	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	11,031	
		MemberYears	7,610.8	
	Male	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	11,151	
		MemberYears	7,627.6	
	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	0	
		MemberYears	0.0	
Year	2014	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	19,019	
		MemberYears	7,024.3	
	2015	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	17,326	
		MemberYears	8,214.2	
Idelalisib and Ofatumumab, SLL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	85,326
			MemberYears	60,194.2
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,024
			MemberYears	6,821.4
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,693
			MemberYears	8,015.4
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,307
			MemberYears	14,698.5

65+ Years			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	42,310
			MemberYears	30,658.9
Sex	Female			
			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	40,483
			MemberYears	28,725.3
Male			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	44,839
			MemberYears	31,466.4
Unknown			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
Year	2014			
			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	73,071
			MemberYears	27,252.3
2015			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	67,683
			MemberYears	32,941.9
Idelalisib and Prednisone, FL	TOTAL	Total	Users	13
			Episodes	13
			Dispensings	13
			Days Supplied	1,595
			Amount Supplied	12
			Eligible Members	22,182
			MemberYears	15,238.4
AgeGroup	18-44 Years			
			Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
45-54 Years			Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	244
			Amount Supplied	2
			Eligible Members	3,545
			MemberYears	2,217.5

55-64 Years		Users	4	
		Episodes	4	
		Dispensings	4	
		Days Supplied	557	
		Amount Supplied	3	
		Eligible Members	6,511	
		MemberYears	4,249.9	
65+ Years		Users	7	
		Episodes	7	
		Dispensings	7	
		Days Supplied	794	
		Amount Supplied	7	
		Eligible Members	10,917	
		MemberYears	7,575.3	
Sex	Female	Users	6	
		Episodes	6	
		Dispensings	6	
		Days Supplied	698	
		Amount Supplied	5	
		Eligible Members	11,031	
		MemberYears	7,610.8	
	Male	Users	7	
		Episodes	7	
		Dispensings	7	
		Days Supplied	897	
		Amount Supplied	7	
		Eligible Members	11,151	
		MemberYears	7,627.6	
	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	0	
		MemberYears	0.0	
Year	2014	Users	8	
		Episodes	8	
		Dispensings	8	
		Days Supplied	1,215	
		Amount Supplied	8	
		Eligible Members	19,019	
		MemberYears	7,024.3	
	2015	Users	5	
		Episodes	5	
		Dispensings	5	
		Days Supplied	380	
		Amount Supplied	4	
		Eligible Members	17,326	
		MemberYears	8,214.2	
Idelalisib and Prednisone, SLL	TOTAL	Total	Users	34
			Episodes	35
			Dispensings	35
			Days Supplied	4,042
			Amount Supplied	32
			Eligible Members	85,326
			MemberYears	60,194.2
AgeGroup	18-44 Years	Users	1	
		Episodes	1	
		Dispensings	1	
		Days Supplied	152	
		Amount Supplied	1	
		Eligible Members	11,024	
		MemberYears	6,821.4	

45-54 Years		Users	3	
		Episodes	3	
		Dispensings	3	
		Days Supplied	462	
		Amount Supplied	3	
		Eligible Members	12,693	
		MemberYears	8,015.4	
55-64 Years		Users	14	
		Episodes	14	
		Dispensings	14	
		Days Supplied	1,453	
		Amount Supplied	12	
		Eligible Members	22,307	
		MemberYears	14,698.5	
65+ Years		Users	16	
		Episodes	17	
		Dispensings	17	
		Days Supplied	1,975	
		Amount Supplied	16	
		Eligible Members	42,310	
		MemberYears	30,658.9	
Sex	Female	Users	14	
		Episodes	15	
		Dispensings	15	
		Days Supplied	1,725	
		Amount Supplied	13	
		Eligible Members	40,483	
		MemberYears	28,725.3	
	Male	Users	20	
		Episodes	20	
		Dispensings	20	
		Days Supplied	2,317	
		Amount Supplied	19	
		Eligible Members	44,839	
		MemberYears	31,466.4	
	Unknown	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	4	
		MemberYears	2.6	
Year	2014	Users	17	
		Episodes	17	
		Dispensings	17	
		Days Supplied	2,445	
		Amount Supplied	16	
		Eligible Members	73,071	
		MemberYears	27,252.3	
	2015	Users	17	
		Episodes	18	
		Dispensings	18	
		Days Supplied	1,597	
		Amount Supplied	15	
		Eligible Members	67,683	
		MemberYears	32,941.9	
Idelalisib and Rituximab, FL	TOTAL	Total	Users	24
			Episodes	24
			Dispensings	24
			Days Supplied	2,544
			Amount Supplied	23
			Eligible Members	22,182
			MemberYears	15,238.4

AgeGroup	18-44 Years	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	99
		Amount Supplied	1
		Eligible Members	2,015
		MemberYears	1,195.7
		45-54 Years	Users
Episodes	5		
Dispensings	5		
Days Supplied	600		
Amount Supplied	5		
Eligible Members	3,545		
MemberYears	2,217.5		
55-64 Years	Users		3
	Episodes	3	
	Dispensings	3	
	Days Supplied	436	
	Amount Supplied	3	
	Eligible Members	6,511	
	MemberYears	4,249.9	
	65+ Years	Users	15
Episodes		15	
Dispensings		15	
Days Supplied		1,409	
Amount Supplied		14	
Eligible Members		10,917	
MemberYears		7,575.3	
Sex		Female	Users
	Episodes		9
	Dispensings		9
	Days Supplied		933
	Amount Supplied		9
	Eligible Members		11,031
	MemberYears		7,610.8
	Male		Users
Episodes		15	
Dispensings		15	
Days Supplied		1,611	
Amount Supplied		14	
Eligible Members		11,151	
MemberYears		7,627.6	
Unknown		Users	0
	Episodes	0	
	Dispensings	0	
	Days Supplied	0	
	Amount Supplied	0	
	Eligible Members	0	
	MemberYears	0.0	
	Year	2014	Users
Episodes			15
Dispensings			15
Days Supplied			1,825
Amount Supplied			14
Eligible Members			19,019
MemberYears			7,024.3
2015			Users
	Episodes	9	
	Dispensings	9	
	Days Supplied	719	
	Amount Supplied	8	
	Eligible Members	17,326	
	MemberYears	8,214.2	

Idelalisib and Rituximab, SLL	TOTAL	Total		
			Users	60
			Episodes	62
			Dispensings	62
			Days Supplied	6,755
			Amount Supplied	57
			Eligible Members	86,698
			MemberYears	60,976.1
	AgeGroup	18-44 Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	129
			Amount Supplied	2
			Eligible Members	11,206
			MemberYears	6,918.1
		45-54 Years	Users	8
			Episodes	8
			Dispensings	8
			Days Supplied	940
			Amount Supplied	8
			Eligible Members	12,933
			MemberYears	8,140.3
		55-64 Years	Users	16
			Episodes	16
			Dispensings	16
			Days Supplied	2,221
			Amount Supplied	15
			Eligible Members	22,742
			MemberYears	14,936.2
		65+ Years	Users	34
			Episodes	36
			Dispensings	36
			Days Supplied	3,465
			Amount Supplied	32
			Eligible Members	42,871
			MemberYears	30,981.4
	Sex	Female	Users	17
			Episodes	17
			Dispensings	17
			Days Supplied	1,987
			Amount Supplied	16
			Eligible Members	41,121
			MemberYears	29,089.2
		Male	Users	43
			Episodes	45
			Dispensings	45
			Days Supplied	4,768
			Amount Supplied	41
			Eligible Members	45,573
			MemberYears	31,884.3
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	32
			Episodes	32
			Dispensings	32
			Days Supplied	4,117
			Amount Supplied	31
			Eligible Members	74,416
			MemberYears	27,766.1

2015			Users	29
			Episodes	30
			Dispensings	30
			Days Supplied	2,638
			Amount Supplied	26
			Eligible Members	68,805
			MemberYears	33,210.0
Idelalisib and Vincristine, FL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,182
			MemberYears	15,238.4
AgeGroup	18-44 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
	45-54 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5
	55-64 Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
	65+ Years		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	10,917
			MemberYears	7,575.3
Sex	Female		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,031
			MemberYears	7,610.8
	Male		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,151
			MemberYears	7,627.6
	Unknown		Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0

Year	2014	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	19,019	
		MemberYears	7,024.3	
	2015	Users	0	
		Episodes	0	
		Dispensings	0	
		Days Supplied	0	
		Amount Supplied	0	
		Eligible Members	17,326	
		MemberYears	8,214.2	
Idelalisib and Vincristine, SLL	TOTAL	Total	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	267
			Amount Supplied	1
			Eligible Members	86,698
			MemberYears	60,976.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,206
			MemberYears	6,918.1
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,933
			MemberYears	8,140.3
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,742
			MemberYears	14,936.2
		65+ Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	267
			Amount Supplied	1
			Eligible Members	42,871
			MemberYears	30,981.4
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	267
			Amount Supplied	1
			Eligible Members	41,121
			MemberYears	29,089.2
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	45,573
			MemberYears	31,884.3

	Unknown	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	4
		MemberYears	2.6
	Year	2014	
		Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	267
		Amount Supplied	1
		Eligible Members	74,416
		MemberYears	27,766.1
	2015	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	68,805
		MemberYears	33,210.0